NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,52.5420875862786,1.9554608945166416,29.38448439535358,1.46811807462444,8.95647120560566,41.536013849221,percent_activity,2,26.869413616817,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.48777301540737,1.48777301540737,0.520248203924875,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.26280460505833,3.4498315184680575,45.09006149708917,1.65408082762922,0.122016065451132,0.927311399399235,log2_fold_induction,2,0.366048196353396,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.32349497926642,1.32349497926642,0.843415936756112,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,77.6487771538935,2.682095886972063,34.65466724841638,1.53976173313924,9.65026114229828,58.6047093738004,percent_activity,2,28.9507834268948,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.31394478863083,1.31394478863083,0.585662050673534,20,cell cycle
APR_HepG2_CellCycleArrest_72h_dn,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,1.68806467460144,1.8204578044391555,48.761929017414076,1.68808087793583,0.0927274815425616,1.68254049569916,log2_fold_induction,2,0.927274815425616,,1.69882384662856,1.59997423820542,1.56880056418765,20,cell cycle
APR_HepG2_CellLoss_24h_dn,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,4.58475766602672,6.925388452335693,61.285164144216544,1.78735535363568,0.066202173316075,3.60401760011407,log2_fold_induction,2,0.66202173316075,,1.45858473256467,1.21548048446001,1.38135034428661,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,7.35613091463068,8.289724995765654,52.94214697661189,1.72380154937917,0.0887379366431112,5.82993064767474,log2_fold_induction,2,0.887379366431112,,1.24109186261337,0.92624665863527,1.18987764501101,20,cell cycle
APR_HepG2_MitoMass_24h_dn,"Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,1.89555364682999,3.809469256589392,52.01439481212683,1.71612354983368,0.0497589957853361,1.63148995587739,log2_fold_induction,2,0.497589957853361,,1.55487784245546,1.33221701305832,1.37314722441044,20,cell morphology
APR_HepG2_MitoMembPot_72h_dn,"Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,2.63123274161423,3.611086173572552,50.557640030597604,1.70378679340705,0.0728654098833392,2.19269395138125,log2_fold_induction,2,0.728654098833392,,1.46997744707986,1.11881680244851,1.16851935821031,20,cell morphology
APR_HepG2_MitoticArrest_24h_up,"Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",,H3F3A,"H3 histone, family 3A",https://www.ncbi.nlm.nih.gov/gene/3020,,,Active,1.98694106091006,1.8026622817946722,45.30955924451642,1.6561898375355,0.110222590275308,1.78978908222861,log2_fold_induction,2,1.10222590275308,,1.69080166078188,1.4024975142604,1.31022711710713,20,cell cycle
APR_HepG2_MitoticArrest_72h_up,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""arrest"".",,H3F3A,"H3 histone, family 3A",https://www.ncbi.nlm.nih.gov/gene/3020,,,Active,3.49584099342259,2.4634808928007144,38.750638769257016,1.58827886585335,0.141906560088972,3.03627281127082,log2_fold_induction,2,1.41906560088972,,1.50197588070725,1.14053701720918,1.09033193590036,20,cell cycle
APR_HepG2_NuclearSize_24h_dn,"Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,0.509510305027185,1.9370481341103871,52.93684493049083,1.72375805351028,0.0102845399297649,0.424591920867189,log2_fold_induction,2,0.263034405833794,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.73538846581827,1.23333761256001,1.33073465916228,20,cell morphology
APR_HepG2_P-H2AX_24h_up,"Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1,H2AFX,"H2A histone family, member X",https://www.ncbi.nlm.nih.gov/gene/3014,,,Active,1.32502208413625,1.6136573469408773,43.66647364849359,1.64014812123581,0.0821129768750588,1.17743780411984,log2_fold_induction,2,0.821129768750588,,1.72590543139637,1.38079824899454,1.25427693016737,20,dna binding
APR_HepG2_P-H2AX_72h_up,"Data from the assay component APR_HepG2_P-H2AX_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1,H2AFX,"H2A histone family, member X",https://www.ncbi.nlm.nih.gov/gene/3014,,,Active,4.70360959473855,4.289188282301373,51.49808387567302,1.71179107025084,0.109661998615151,3.91967466228447,log2_fold_induction,2,1.09661998615151,,1.48027487594338,1.20864841684797,1.2845479695489,20,dna binding
APR_HepG2_StressKinase_72h_up,"Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",NP_002219.1,JUN,jun proto-oncogene,https://www.ncbi.nlm.nih.gov/gene/3725,,,Active,1.93257412068489,1.776275255326028,61.61874079842076,1.7897128191045,0.108799248027028,1.61047843401294,log2_fold_induction,2,1.08799248027028,,1.8232089598633,1.57894744527225,1.49909448688489,20,cell cycle
ArunA_Migration_hNC_dn,"Data from the assay component ArunA_Migration_hNC was analyzed at the endpoint, ArunA_Migration_hNC_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of distribution reporter, loss-of-signal activity can be used to understand the cell migration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is migration.",, , , ,,,Active,49.28196014535629,1.5773910692122024,1.5257474490714782,0.18348265252336649,10.414234218186872,49.748683580660604,log2_fold_induction,1,31.242702654560617,"[""Less than 50% efficacy""]",0.32671064228902946,0.32671064228902946,-0.38950301799533893,100,neurodevelopment
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1","FOS | JUN","FBJ murine osteosarcoma viral oncogene homolog , jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/2353 , https://www.ncbi.nlm.nih.gov/gene/3725",,,Active,0.8118422589178522,1.3535348137445666,24.240708674325653,1.3845453122289926,0.11995882938125292,0.6765352157705906,log2_fold_induction,1.84509804001426,0.5997941469062646,"[""Borderline active""]",2.014687174242924,1.246462303052384,0.052944312464856313,20,dna binding
ATG_AP_2_CIS_dn,ATG_AP_2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_003211.1|NP_003212.2|NP_758438.2","TFAP2A | TFAP2B | TFAP2D","transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) , transcription factor AP-2 beta (activating enhancer binding protein 2 beta) , transcription factor AP-2 delta (activating enhancer binding protein 2 delta)","https://www.ncbi.nlm.nih.gov/gene/7020 , https://www.ncbi.nlm.nih.gov/gene/7021 , https://www.ncbi.nlm.nih.gov/gene/83741",,,Active,0.42841733577251717,1.3429935286612025,53.96631519174839,1.7321227655448674,0.06380035742980772,0.35701444659599363,log2_fold_induction,2.30102999566398,0.3190017871490386,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",2.325538384695227,1.6135788724369378,0.5136048822585149,20,dna binding
ATG_BRE_CIS_up,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.",NP_005891.1,SMAD1,SMAD family member 1,https://www.ncbi.nlm.nih.gov/gene/4086,,,Active,2.226084618781273,2.430712737466218,75.09169649257578,1.8755919161409293,0.183163117917566,2.22520111343009,log2_fold_induction,2.30102999566398,0.91581558958783,,1.8561478543580556,1.815033277329414,1.756311563644825,20,dna binding
ATG_CAR_TRANS_dn,ATG_CAR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001070948.1,NR1I3,"nuclear receptor subfamily 1, group I, member 3",https://www.ncbi.nlm.nih.gov/gene/9970,,,Active,1.6384621139472122,1.624678002352258,60.892894064118245,1.7845666153126685,0.20169684227582294,1.3653850949917619,log2_fold_induction,2.30102999566398,1.0084842113791146,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",2.116416326037085,1.4070955193606314,0.2348982595231397,20,nuclear receptor
ATG_chERa_XSP1_up,"The assay endpoint ATG_chERa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/396099,,,Active,1.5560883082048085,2.065943526489952,4.79527830286549,0.6808138173234475,0.25106983617127393,1.3492798760345879,log2_fold_induction,1.84509804001426,0.7532095085138217,,0.6401587035790224,0.6401587035790224,-0.7179949720245296,20,nuclear receptor
ATG_CRE_CIS_up,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006359.3,CREB3,cAMP responsive element binding protein 3,https://www.ncbi.nlm.nih.gov/gene/10488,,,Active,1.8627867902126631,2.5498715449240876,64.47353564812299,1.809381487030808,0.14610828486013952,1.552322325178526,log2_fold_induction,2.30102999566398,0.7305414243006976,,1.6282219156657067,1.3221009811929179,0.9009523444902701,20,dna binding
ATG_DR4_LXR_CIS_dn,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_009052.3|NP_005684.2","NR1H2 | NR1H3","nuclear receptor subfamily 1, group H, member 2 , nuclear receptor subfamily 1, group H, member 3","https://www.ncbi.nlm.nih.gov/gene/7376 , https://www.ncbi.nlm.nih.gov/gene/10062",,,Active,1.1250434959594766,1.9020154491910128,24.36908248092959,1.3868391778933546,0.11830014277097414,0.9949073415252603,log2_fold_induction,1.84509804001426,0.5915007138548707,"[""Hit-call potentially confounded by overfitting""]",1.3924392528108318,1.344767379506215,1.2675200453013888,20,nuclear receptor
ATG_EGR_CIS_up,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_001955.1,EGR1,early growth response 1,https://www.ncbi.nlm.nih.gov/gene/1958,,,Active,2.1273870192846998,3.0492769647960496,74.55732423303175,1.872490313352342,0.13953386614895374,1.7728225160981763,log2_fold_induction,2.30102999566398,0.6976693307447688,,1.6453243042717873,1.4271360496995373,1.1768195669354495,20,dna binding
ATG_ERE_CIS_dn,ATG_ERE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,0.6881141234658545,1.3177889885899632,93.13318840482027,1.9691044712349237,0.1044346446090945,0.686592071651086,log2_fold_induction,2.30102999566398,0.5221732230454725,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",2.0313630867475743,1.959369717734722,1.8497743791392722,20,nuclear receptor
ATG_ERRg_TRANS_dn,ATG_ERRg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001429.2,ESRRG,estrogen-related receptor gamma,https://www.ncbi.nlm.nih.gov/gene/2104,,,Active,1.6845391766195643,1.241242721806212,163.664519809538,2.213954540615203,0.27142784356765987,1.4037826478640512,log2_fold_induction,2.30102999566398,1.3571392178382993,"[""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",2.2911477691805207,2.2103456405255297,2.0946742176157036,20,nuclear receptor
ATG_Ets_CIS_dn,ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005229.1,ETS1,v-ets avian erythroblastosis virus E26 oncogene homolog 1,https://www.ncbi.nlm.nih.gov/gene/2113,,,Active,0.6257878865984399,1.7271910523908067,132.18609606755038,2.1211857764907585,0.07246307647694375,0.5214899060497438,log2_fold_induction,2.30102999566398,0.3623153823847187,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",2.156789814184885,2.0507128489971787,1.875616391321043,20,dna binding
ATG_FoxO_CIS_dn,ATG_FoxO_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_002006.2|NP_001446.1","FOXO1 | FOXO3","forkhead box O1 , forkhead box O3","https://www.ncbi.nlm.nih.gov/gene/2308 , https://www.ncbi.nlm.nih.gov/gene/2309",,,Active,1.6212665310130165,3.4422995938918253,146.55538733222474,2.166001787603207,0.09419671279570589,1.3510554575925044,log2_fold_induction,2.30102999566398,0.4709835639785295,"[""Only one conc above baseline, active""]",2.091082281102919,2.0354972516702508,1.9816501274459286,20,dna binding
ATG_frAR_XSP1_dn,ATG_frAR_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,,ar.L,androgen receptor L homeolog,https://www.ncbi.nlm.nih.gov/gene/399456,,,Active,1.8889133562903604,4.075368444375144,1.581141030725754,0.19897060879010267,0.15449837088942256,2.0923673439822057,log2_fold_induction,1.30102999566398,0.4634951126682677,,-0.11113241859239073,-0.11113241859239073,-0.4075373175090212,20,nuclear receptor
ATG_frAR_XSP2_dn,ATG_frAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,ar.L,androgen receptor L homeolog,https://www.ncbi.nlm.nih.gov/gene/399456,,,Active,1.3024122830031175,2.278197574265655,4.573847844949963,0.6602817131352393,0.1905617987534044,1.196249841125465,log2_fold_induction,1.84509804001426,0.5716853962602132,,0.5544890091353188,0.5544890091353188,-0.28675205620875266,20,nuclear receptor
ATG_frER1_XSP1_up,"The assay endpoint ATG_frER1_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr1.L,estrogen receptor 1 L homeolog,https://www.ncbi.nlm.nih.gov/gene/398734,,,Active,1.483547865922048,1.7689374752930578,4.090219297148324,0.6117465933345384,0.2795553614609377,1.2362900135377535,log2_fold_induction,1.30102999566398,0.8386660843828131,,0.7440422587018091,0.7440422587018091,-0.4945831266515187,20,nuclear receptor
ATG_frER2_XSP1_up,"The assay endpoint ATG_frER2_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2.L,estrogen receptor 2 L homeolog,https://www.ncbi.nlm.nih.gov/gene/100174814,,,Active,1.8934269671821786,4.117111683255168,32.149384072117826,1.5071726569914126,0.15329735284107007,1.5778558065812234,log2_fold_induction,1.84509804001426,0.45989205852321025,"[""Hit-call potentially confounded by overfitting""]",1.2683325985280733,1.2683325985280733,1.0455822852699823,20,nuclear receptor
ATG_GLI_CIS_up,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005260.1,GLI1,GLI family zinc finger 1,https://www.ncbi.nlm.nih.gov/gene/2735,,,Active,1.243395618504489,3.2344008839141067,91.07298402916187,1.9593895665765853,0.07688568381788191,1.2411011195909292,log2_fold_induction,2.30102999566398,0.38442841908940956,"[""Only one conc above baseline, active""]",1.915742197354879,1.8790691318388,1.8401031518156614,20,dna binding
ATG_GRE_CIS_dn,ATG_GRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000167.1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",https://www.ncbi.nlm.nih.gov/gene/2908,,,Active,0.93726303194541,2.2819226892259734,131.59542505579694,2.119240791196181,0.08214678230517344,0.7810525283769231,log2_fold_induction,2.30102999566398,0.41073391152586725,"[""Only one conc above baseline, active""]",2.091153530238185,2.002671323691874,1.8707556941016326,20,nuclear receptor
ATG_hAR_XSP1_dn,ATG_hAR_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.3862846253950591,2.316252934662996,7.619010262725687,0.8818985585634475,0.19950104248822853,1.4778607936642003,log2_fold_induction,2.30102999566398,0.5985031274646856,,0.7886907192139135,0.7886907192139135,0.13660473324694455,20,nuclear receptor
ATG_hAR_XSP2_dn,ATG_hAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,1.635180593910182,2.4113170233572427,49.951344416506245,1.6985471815472393,0.2260425289127603,1.3626504949272649,log2_fold_induction,2.30102999566398,0.6781275867382809,,1.5305735615084106,1.5305735615084106,0.6272822285429158,20,nuclear receptor
ATG_hERa_XSP1_up,"The assay endpoint ATG_hERa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,1.5686662354567966,2.1251348283099953,5.237583252311925,0.7191309392167995,0.24604968032456118,1.307221862881182,log2_fold_induction,1.84509804001426,0.7381490409736835,,0.6204397022298627,0.6204397022298627,-1.1200677223100355,20,nuclear receptor
ATG_hERa_XSP2_up,"The assay endpoint ATG_hERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,1.016404325102425,1.6257606341014048,7.193425285088414,0.8569357371403802,0.20839564853166204,0.847003604313476,log2_fold_induction,1.30102999566398,0.6251869455949861,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",0.8823932377824036,0.8823932377824036,0.7376154407759091,20,nuclear receptor
ATG_hERb_XSP1_up,"The assay endpoint ATG_hERb_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,1.5366000654308771,1.8560265752826288,11.583274519968423,1.0638313491085116,0.27596588789807414,1.280500054635295,log2_fold_induction,1.30102999566398,0.8278976636942224,"[""Hit-call potentially confounded by overfitting""]",1.0853929337498172,1.0853929337498172,0.7590743975410541,20,nuclear receptor
ATG_HIF1a_CIS_up,"Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001521.1,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",https://www.ncbi.nlm.nih.gov/gene/3091,"[122,123,220,150,122,123,220,150]",[801],Active,0.9807002753840666,1.2811471898350584,35.38766175961292,1.548851867569817,0.15309720587379613,0.9631119706257293,log2_fold_induction,2.30102999566398,0.7654860293689807,,1.7927102402737345,1.5244735117668624,1.1265795469094202,20,dna binding
ATG_HNF4a_TRANS_dn,ATG_HNF4a_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000448.3,HNF4A,"hepatocyte nuclear factor 4, alpha",https://www.ncbi.nlm.nih.gov/gene/3172,,,Active,1.858643523919389,1.310621611528835,55.184107739666125,1.7418140249266354,0.2836277851013442,1.6389731093055144,log2_fold_induction,2.30102999566398,1.418138925506721,"[""Borderline active"",""Hit-call potentially confounded by overfitting""]",2.0886429097262167,1.691618948852025,1.0900229523807927,20,nuclear receptor
ATG_HNF6_CIS_dn,ATG_HNF6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_004489.1,ONECUT1,one cut homeobox 1,https://www.ncbi.nlm.nih.gov/gene/3175,,,Active,1.1973328612899659,3.3335416320577296,163.2858045587638,2.2129484304821054,0.07183548270557376,0.9977773912706289,log2_fold_induction,2.30102999566398,0.3591774135278688,"[""Only one conc above baseline, active""]",2.166553622235266,2.129923583624038,2.09264944356286,20,dna binding
ATG_hPPARg_XSP1_up,"The assay endpoint ATG_hPPARg_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,,,Active,0.8675782377517667,1.2117231924404086,15.532957107567555,1.1912541429948362,0.23866238405061954,1.0326545902947577,log2_fold_induction,1.84509804001426,0.7159871521518586,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.4682317148192379,1.4682317148192379,0.7992467282515623,20,nuclear receptor
ATG_hPPARg_XSP2_up,"The assay endpoint ATG_hPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,,,Active,1.1037767752431848,1.7878272208805488,53.17008709052174,1.7256673716721256,0.20579482594884976,0.9198139794727328,log2_fold_induction,2.30102999566398,0.6173844778465493,"[""Only one conc above baseline, active""]",1.8351520911532795,1.8351520911532795,0.716920007932683,20,nuclear receptor
ATG_HSE_CIS_up,"Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is heat shock protein.",NP_005517.1,HSF1,heat shock transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/3297,,,Active,3.3183156012713875,6.986583264218319,110.05606935319283,2.041613997947225,0.09499108436211133,3.290631964397824,log2_fold_induction,2.30102999566398,0.47495542181055667,"[""Only one conc above baseline, active""]",1.9444537919230924,1.9132073789813115,1.922317934153894,20,dna binding
ATG_IR1_CIS_dn,ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001193922.1,NR1H4,"nuclear receptor subfamily 1, group H, member 4",https://www.ncbi.nlm.nih.gov/gene/9971,,,Active,1.255818556726277,2.563559589013159,86.61994221821101,1.9376178896879763,0.09797459455270192,1.254266386672771,log2_fold_induction,2.30102999566398,0.4898729727635096,"[""Only one conc above baseline, active""]",1.9133530603208893,1.8732548935186923,1.8183349966531015,20,nuclear receptor
ATG_ISRE_CIS_dn,ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002189.1,IRF1,interferon regulatory factor 1,https://www.ncbi.nlm.nih.gov/gene/3659,,,Active,1.0772624421976795,1.5236580851094077,21.231072914981514,1.3269719418476815,0.14140474857524557,1.077176935417434,log2_fold_induction,1.84509804001426,0.7070237428762278,"[""Only one conc above baseline, active""]",1.362090973041756,1.303551938392203,1.207691601489071,20,dna binding
ATG_LXRa_TRANS_up,"Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_LXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_005684.2,NR1H3,"nuclear receptor subfamily 1, group H, member 3",https://www.ncbi.nlm.nih.gov/gene/10062,"[61,58,34,34,61,58]",[483],Active,1.3864158438151235,1.2124860013955177,1.504982120661854,0.17753134049861927,0.2286897897739719,1.15534653651942,log2_fold_induction,0.301029995663981,1.1434489488698594,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",0.26167742177540687,0.1764123965017369,0.058162546844958085,20,nuclear receptor
ATG_mPPARg_XSP1_up,"The assay endpoint ATG_mPPARg_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",,Pparg,peroxisome proliferator activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/19016,,,Active,1.0492630344635916,1.7881219827974015,24.02737293557494,1.3807062892411408,0.19559870533778076,0.9950223238456114,log2_fold_induction,2.30102999566398,0.5867961160133423,,1.45526539043564,1.45526539043564,0.6926700107507855,20,nuclear receptor
ATG_mPPARg_XSP2_up,"The assay endpoint ATG_mPPARg_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",,Pparg,peroxisome proliferator activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/19016,,,Active,0.7417681750123708,1.4171725725487012,21.092831800236745,1.32413488949092,0.17447138275671079,0.6181401458815552,log2_fold_induction,2.30102999566398,0.5234141482701323,"[""Borderline active""]",1.878956251482725,1.878956251482725,-0.07027145033651072,20,nuclear receptor
ATG_mPXR_XSP1_up,"The assay endpoint ATG_mPXR_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,,,Active,1.3191704002988933,2.086073130182666,0.463542748126732,-0.3339102088345306,0.21079005352405533,1.4059411233188592,log2_fold_induction,0.301029995663981,0.632370160572166,,-0.3470288945004718,-0.3470288945004718,-0.6830103889897782,20,nuclear receptor
ATG_mPXR_XSP2_up,"The assay endpoint ATG_mPXR_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PXR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,,,Active,1.185275972794277,2.191219794140383,0.7240923757323616,-0.14020602536130178,0.18030687381884508,1.1346082037744958,log2_fold_induction,0.845098040014257,0.5409206214565352,,-0.185898260206863,-0.185898260206863,-0.7139707564631971,20,nuclear receptor
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2,MTF1,metal-regulatory transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/4520,,,Active,4.566933542940339,7.593432466263937,105.52093554338984,2.023338632988751,0.12028640705584168,3.805777952558354,log2_fold_induction,2.30102999566398,0.6014320352792084,,1.690051858629859,1.5893765154849315,1.6350686798060656,20,dna binding
ATG_Myb_CIS_dn,ATG_Myb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,CAE82649.1,MYB,v-myb avian myeloblastosis viral oncogene homolog,https://www.ncbi.nlm.nih.gov/gene/4602,,,Active,0.4224903218212268,1.4333683545286613,91.46731409770905,1.9612659263828431,0.05895069756303578,0.42168234203779864,log2_fold_induction,2.30102999566398,0.2947534878151789,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",2.006665371678736,1.9434276158834767,1.8419682836514188,20,dna binding
ATG_Myc_CIS_up,"Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myc_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_002458.2,MYC,v-myc avian myelocytomatosis viral oncogene homolog,https://www.ncbi.nlm.nih.gov/gene/4609,,,Active,0.8105424729785393,1.6618829301143316,89.81582478296613,1.9533528623959877,0.09754507472109084,0.8092011023694153,log2_fold_induction,2.30102999566398,0.4877253736054542,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.975762114761657,1.9223526435642027,1.8340358101423424,20,dna binding
ATG_NFI_CIS_up,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.",NP_001128145.1,NFIA,nuclear factor I/A,https://www.ncbi.nlm.nih.gov/gene/4774,,,Active,1.1953627615956062,2.8374569390453344,163.603111538115,2.21379155918239,0.08425592262892893,0.9961356359728437,log2_fold_induction,2.30102999566398,0.4212796131446447,"[""Only one conc above baseline, active""]",2.1807643619502572,2.1423410194942445,2.0945110614432796,20,dna binding
ATG_NRF1_CIS_up,"Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.",NP_005002.3,NRF1,nuclear respiratory factor 1,https://www.ncbi.nlm.nih.gov/gene/4899,,,Active,0.5132605509635416,1.2765611893220026,163.79378887237604,2.2142974291118405,0.08041299629924369,0.4277171308305506,log2_fold_induction,2.30102999566398,0.40206498149621844,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy""]",2.284073524885674,2.2077779502771433,2.095017115353653,20,dna binding
ATG_NURR1_TRANS_up,"Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NURR1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",NP_006177.1,NR4A2,"nuclear receptor subfamily 4, group A, member 2",https://www.ncbi.nlm.nih.gov/gene/4929,,,Active,2.4556891655401376,2.8462754238583603,29.118702580494073,1.464172020548801,0.17255457043656366,2.046407637964067,log2_fold_induction,2.30102999566398,0.8627728521828183,,1.1495698014512057,0.7868624875907633,0.33683154212873156,20,nuclear receptor
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3,POU2F1,POU class 2 homeobox 1,https://www.ncbi.nlm.nih.gov/gene/5451,,,Active,2.937782511998666,4.334993881625495,102.0489632982275,2.00880859713493,0.13553802345377633,2.44815209334257,log2_fold_induction,2.30102999566398,0.6776901172688816,,1.7815099364490674,1.6637343067326749,1.5941649336350476,20,dna binding
ATG_p53_CIS_dn,ATG_p53_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,,,Active,1.167021863862952,1.8257210438751041,39.49940014612358,1.5965905003047742,0.12784229746138445,1.1154772174199346,log2_fold_induction,2.30102999566398,0.6392114873069222,,1.643705116879393,1.4208366659323328,1.056003960692479,20,dna binding
ATG_Pax6_CIS_up,"Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is paired box protein.",NP_000271.1,PAX6,paired box 6,https://www.ncbi.nlm.nih.gov/gene/5080,,,Active,1.6397100705250343,2.5833518841629672,49.79316659777363,1.6971697461230089,0.12694438419923712,1.4975715193588062,log2_fold_induction,2.30102999566398,0.6347219209961856,,1.579313332572613,1.390538056459088,1.1336611751471408,20,dna binding
ATG_PBREM_CIS_up,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001070948.1,NR1I3,"nuclear receptor subfamily 1, group I, member 3",https://www.ncbi.nlm.nih.gov/gene/9970,"[8,107,58,8,107,58]","[456,715]",Active,0.7143653339104445,1.4900645836695554,3.8528990266079286,0.5857876275539793,0.09588380822409588,0.5953044449426106,log2_fold_induction,2.30102999566398,0.4794190411204794,"[""Hit-call potentially confounded by overfitting""]",1.2286178129419594,0.2303433055108402,-1.3945915803527529,20,nuclear receptor
ATG_PPARg_TRANS_up,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2,PPARG,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/5468,"[72,36,58,34,163,34,36,58,72,163]",,Active,1.4224025504695126,1.2396040706922302,11.71309826684517,1.068671786807593,0.2294930428350727,2.011121472949028,log2_fold_induction,1.30102999566398,1.1474652141753636,"[""Hit-call potentially confounded by overfitting""]",1.1462350128203478,1.0652017907163167,0.9493914730859077,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,3.4962844221014633,5.246485523875587,0.3879076559172344,-0.41127164888718887,0.13328100901796647,3.5298052209674924,log2_fold_induction,0.845098040014257,0.6664050450898323,,-0.787209575778439,-0.9434102109349929,-0.9824802724506492,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,"[8,11,60,8,11,60]",,Active,2.564101609863501,1.9906869874341568,0.3584676525034991,-0.4455500282055632,0.2576097222766731,2.764111736179328,log2_fold_induction,0.845098040014257,1.2880486113833656,"[""Hit-call potentially confounded by overfitting""]",-0.4432101281731978,-0.6557721652564888,-0.9950293787258541,20,nuclear receptor
ATG_RARa_TRANS_dn,ATG_RARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_000955.1,RARA,"retinoic acid receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/5914,,,Active,3.4371048250182676,2.9992116664583466,82.03146363745613,1.9139804604720965,0.22920055049512475,3.4343547067772464,log2_fold_induction,2.30102999566398,1.1460027524756238,"[""Hit-call potentially confounded by overfitting""]",1.8763698335728067,1.838734234589067,1.794689744420905,20,nuclear receptor
ATG_RARb_TRANS_dn,ATG_RARb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001277145.1,RARB,"retinoic acid receptor, beta",https://www.ncbi.nlm.nih.gov/gene/5915,,,Active,1.150156654300519,1.0708324230070057,76.80272744100073,1.8853766430984873,0.21481543322544586,1.1496133796536427,log2_fold_induction,2.30102999566398,1.0740771661272293,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active""]",2.0290976786669286,1.898537258516482,1.7660962897088006,20,nuclear receptor
ATG_RORE_CIS_up,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.","NP_599023.1|NP_008845.2|NP_005051.2","RORA | RORB | RORC","RAR-related orphan receptor A , RAR-related orphan receptor B , RAR-related orphan receptor C","https://www.ncbi.nlm.nih.gov/gene/6095 , https://www.ncbi.nlm.nih.gov/gene/6096 , https://www.ncbi.nlm.nih.gov/gene/6097",,,Active,0.9967114448313013,1.4557438376884744,24.848841316667755,1.395306142706798,0.13693500450105905,0.8306455720438249,log2_fold_induction,1.84509804001426,0.6846750225052953,"[""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.4379660427542367,1.3760320761443763,1.2760258271182785,20,nuclear receptor
ATG_RORg_TRANS_dn,ATG_RORg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005051.2,RORC,RAR-related orphan receptor C,https://www.ncbi.nlm.nih.gov/gene/6097,,,Active,1.4256706398050436,1.217787611035185,6.737979561066027,0.8285296892616488,0.23414109765711066,1.1880589301675457,log2_fold_induction,1.30102999566398,1.1707054882855532,"[""Hit-call potentially confounded by overfitting"",""Borderline active""]",0.9115396725021039,0.8269386336247848,0.7088686258193353,20,nuclear receptor
ATG_RXRa_TRANS_dn,ATG_RXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002948.1,RXRA,"retinoid X receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/6256,,,Active,1.6379961799460423,1.7771610110561917,163.61494533737923,2.213822971591422,0.18433852304384712,1.3649968167792486,log2_fold_induction,2.30102999566398,0.9216926152192356,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",2.227509270069491,2.177236928945653,2.094541140961482,20,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1,RXRB,"retinoid X receptor, beta",https://www.ncbi.nlm.nih.gov/gene/6257,,,Active,4.027251067011736,4.054024262385111,11.261551668803852,1.0515982337455125,0.19867917932204862,3.356042555871747,log2_fold_induction,1.30102999566398,0.9933958966102431,"[""Hit-call potentially confounded by overfitting""]",0.8900015649274845,0.7982499576148833,0.7335715026054516,20,nuclear receptor
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2,SP1,Sp1 transcription factor,https://www.ncbi.nlm.nih.gov/gene/6667,"[148,148]",,Active,0.6363564795765344,1.2111926177550794,72.60579304978431,1.8609712734436683,0.10507931938290839,0.6361624968474073,log2_fold_induction,2.30102999566398,0.525396596914542,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.9454145515778942,1.8599675830097524,1.7416512259176853,20,dna binding
ATG_SREBP_CIS_up,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_004167.3,SREBF1,sterol regulatory element binding transcription factor 1,https://www.ncbi.nlm.nih.gov/gene/6720,"[62,61,58,34,34,62,61,58]",,Active,1.0569490286270726,2.908963512463792,26.764799269496706,1.4275639906121524,0.07266842805682862,0.8807908573232004,log2_fold_induction,2.30102999566398,0.3633421402841431,,1.048528464374288,0.6375411548126665,0.13947685469583337,20,dna binding
ATG_STAT3_CIS_dn,ATG_STAT3_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_644805.1,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),https://www.ncbi.nlm.nih.gov/gene/6774,,,Active,1.2050420810208133,2.7476106523581176,163.59580295906798,2.2137721576782248,0.08771563612818246,1.0042017359786162,log2_fold_induction,2.30102999566398,0.4385781806409123,"[""Only one conc above baseline, active""]",2.1834642511707387,2.144541318316808,2.0944827083267907,20,dna binding
ATG_TCF_b_cat_CIS_dn,ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_003193.2|NP_001139746.1|NP_057353.1|NP_112573.1","TCF7 | TCF7L2 | LEF1 | TCF7L1","transcription factor 7 (T-cell specific, HMG-box) , transcription factor 7-like 2 (T-cell specific, HMG-box) , lymphoid enhancer-binding factor 1 , transcription factor 7-like 1 (T-cell specific, HMG-box)","https://www.ncbi.nlm.nih.gov/gene/6932 , https://www.ncbi.nlm.nih.gov/gene/6934 , https://www.ncbi.nlm.nih.gov/gene/51176 , https://www.ncbi.nlm.nih.gov/gene/83439",,,Active,1.6968279191111613,2.456337655195799,79.91256655396191,1.902615079137605,0.13815917494257557,1.499952159046784,log2_fold_induction,2.30102999566398,0.6907958747128778,,1.8287412598629602,1.6806680632507194,1.4708336195459124,20,dna binding
ATG_trAR_XSP1_dn,ATG_trAR_XSP1_dn was not developed or optimized to detect loss of signal. Use data with caution.,,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/101947425,,,Active,1.429205426082842,2.560375227937822,111.8102973872107,2.048481802588902,0.186067184018955,1.1910045219104404,log2_fold_induction,2.30102999566398,0.5582015520568651,"[""Only one conc above baseline, active""]",1.9781456761718632,1.9781456761718632,1.7011338089424448,20,nuclear receptor
ATG_trERa_XSP1_up,"The assay endpoint ATG_trERa_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/101933533,,,Active,1.5279312629413895,1.982534143954133,5.593007923367555,0.7476454345745149,0.25689868824385115,1.4345271735122058,log2_fold_induction,1.84509804001426,0.7706960647315535,,0.7537863724924878,0.7537863724924878,-0.01812522541315109,20,nuclear receptor
ATG_trERa_XSP2_up,"The assay endpoint ATG_trERa_XSP2_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/101933533,,,Active,1.1712895826531873,1.3017552087134336,17.587175598043228,1.2451960997943823,0.29992571435167914,0.9760746536614799,log2_fold_induction,1.84509804001426,0.8997771430550374,"[""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.6379503935563053,1.6379503935563053,0.5249380381754463,20,nuclear receptor
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",https://www.ncbi.nlm.nih.gov/gene/7421,,,Active,1.6048590258669853,2.210015647439354,3.1603121746720153,0.49972998421370785,0.1452350826317871,1.6167689090499646,log2_fold_induction,1.84509804001426,0.7261754131589355,,0.3796653915642372,-0.12194579563730579,-0.8841252283140754,20,nuclear receptor
ATG_VDR_TRANS_up,"Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1,VDR,"vitamin D (1,25- dihydroxyvitamin D3) receptor",https://www.ncbi.nlm.nih.gov/gene/7421,,,Active,1.1101755351809877,1.3040412567358806,73.51085867115708,1.8663514957188208,0.17026693433915513,1.1098025705280343,log2_fold_induction,2.30102999566398,0.8513346716957757,"[""Borderline active"",""Hit-call potentially confounded by overfitting""]",1.9309849838788053,1.85767063120705,1.7470710841648633,20,nuclear receptor
ATG_Xbp1_CIS_up,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005071.2,XBP1,X-box binding protein 1,https://www.ncbi.nlm.nih.gov/gene/7494,,,Active,2.357083977269915,4.001744685035967,104.03464716389466,2.01717799858931,0.11780281666064009,1.9642366477986029,log2_fold_induction,2.30102999566398,0.5890140833032005,,1.8201525901707987,1.7061667879119389,1.6233356056610917,20,dna binding
ATG_zfAR_XSP2_dn,ATG_zfAR_XSP2_dn was not developed or optimized to detect loss of signal. Use data with caution.,,ar,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/100005148,,,Active,1.1141958987053404,1.3530218285247013,35.11378909098997,1.545477696241732,0.2744956696720431,1.0602369438371968,log2_fold_induction,2.30102999566398,0.8234870090161293,"[""Only one conc above baseline, active""]",1.8421290801918033,1.8421290801918033,0.9194751803681149,20,nuclear receptor
ATG_zfER2b_XSP1_up,"The assay endpoint ATG_zfER2b_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ER. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,esr2b,estrogen receptor 2b,https://www.ncbi.nlm.nih.gov/gene/317733,,,Active,2.6583095322348664,4.890128669941166,18.674544857962555,1.2712500258510717,0.18120242578858012,2.6692984631017214,log2_fold_induction,2.30102999566398,0.5436072773657403,,1.0091705489525995,1.0091705489525995,0.847347225007633,20,nuclear receptor
ATG_zfPPARg_XSP1_up,"The assay endpoint ATG_zfPPARg_XSP1_up was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARg. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay  endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",,pparg,peroxisome proliferator-activated receptor gamma,https://www.ncbi.nlm.nih.gov/gene/557037,,,Active,0.7518991917933486,1.633417027945151,86.26352990465791,1.93582722550885,0.1534409520919555,0.6265826601083258,log2_fold_induction,2.30102999566398,0.46032285627586644,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",2.0653961240473913,2.0653961240473913,1.3123589931291864,20,nuclear receptor
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.29455337995170533,2.507834450626785,39.99999999999999,1.6020599913279623,0.0391510930713,0.19789664499999998,log10_fold_induction,1.60205999132796,0.1174532792139,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.09946702098744886,20,cell cycle
BSK_3C_TissueFactor_up,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1,F3,"coagulation factor III (thromboplastin, tissue factor)",https://www.ncbi.nlm.nih.gov/gene/2152,,,Active,0.33168747599903425,2.5477059101091624,10,1,0.04339688170481999,0.2728657,log10_fold_induction,1.60205999132796,0.13019064511446,"[""Less than 50% efficacy""]",1,1,-0.2189085495428753,20,cytokine
BSK_3C_Vis_down,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,0.1499264807961812,1.893459477841578,39.99999999999999,1.6020599913279623,0,0.124938734,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.3953364013358336,20,cell morphology
BSK_BE3C_MMP1_up,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.17573858770063924,1.909852306674213,10,1,0.030672282369078,0.17311431500000002,log10_fold_induction,1.60205999132796,0.092016847107234,"[""Less than 50% efficacy""]",1,1,0.3567852172439845,20,protease
BSK_CASM3C_Proliferation_down,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.15486193190270559,1.592472636759511,39.99999999999999,1.6020599913279623,0.032415404055299996,0.121107875,log10_fold_induction,1.60205999132796,0.09724621216589999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.6268703140034818,20,cell cycle
BSK_hDFCGF_CollagenIII_down,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",NP_000081.1,COL3A1,"collagen, type III, alpha 1",https://www.ncbi.nlm.nih.gov/gene/1281,,,Active,0.24383320797891078,1.7226720768281725,40.000000000000014,1.6020599913279625,0.047181200117099996,0.19880545500000002,log10_fold_induction,1.60205999132796,0.14154360035129998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.23916891191122247,20,cell adhesion molecules
BSK_hDFCGF_MMP1_up,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1,MMP1,matrix metallopeptidase 1 (interstitial collagenase),https://www.ncbi.nlm.nih.gov/gene/4312,,,Active,0.14630291982640128,1.840330336333559,40.000000000000014,1.6020599913279625,0.026499394689809996,0.10718245,log10_fold_induction,1.60205999132796,0.07949818406942999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.18469963253645405,20,protease
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.4165032116050409,3.0737431988129873,40.000000000000014,1.6020599913279625,0.0451678604517,0.41297655,log10_fold_induction,1.60205999132796,0.1355035813551,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.8174759889251441,20,cell cycle
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2,CD38,CD38 molecule,https://www.ncbi.nlm.nih.gov/gene/952,,,Active,0.15187871605496406,1.9181147511067733,40.000000000000014,1.6020599913279625,0.0243080164845,0.15186099,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.001994990945352,20,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1,CD40,"CD40 molecule, TNF receptor superfamily member 5",https://www.ncbi.nlm.nih.gov/gene/958,,,Active,0.23421131985026172,2.3491951331166994,40.000000000000014,1.6020599913279625,0.0332328459435,0.16951095,log10_fold_induction,1.60205999132796,0.09969853783049999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.6297195848096647,20,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1,CD69,CD69 molecule,https://www.ncbi.nlm.nih.gov/gene/969,,,Active,0.15133603193912895,1.4293291750543318,40.000000000000014,1.6020599913279625,0.03529302057225,0.11800306,log10_fold_induction,1.60205999132796,0.10587906171674999,"[""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,-2.2195556682046855,20,cytokine
BSK_SAg_Eselectin_down,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2,SELE,selectin E,https://www.ncbi.nlm.nih.gov/gene/6401,,,Active,0.4201819199171435,3.661509799734284,40.000000000000014,1.6020599913279625,0.038252154885,0.302963975,log10_fold_induction,1.60205999132796,0.114756464655,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.6464185075156919,20,cell adhesion molecules
BSK_SAg_IL8_down,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1,CXCL8,chemokine (C-X-C motif) ligand 8,https://www.ncbi.nlm.nih.gov/gene/3576,,,Active,0.3454646638666611,2.2997919443847,40.000000000000014,1.6020599913279625,0.050071872038999994,0.27068519999999996,log10_fold_induction,1.60205999132796,0.150215616117,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.6450901305874917,20,cytokine
BSK_SAg_MCP1_down,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1,CCL2,chemokine (C-C motif) ligand 2,https://www.ncbi.nlm.nih.gov/gene/6347,,,Active,0.24766563591658497,2.6016594354875133,40.000000000000014,1.6020599913279625,0.031731751991099996,0.20225178500000002,log10_fold_induction,1.60205999132796,0.09519525597329999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.7899320084760197,20,cytokine
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.46048329190976955,3.8476291247852275,40.000000000000014,1.6020599913279625,0.0398932500141,0.40083967499999995,log10_fold_induction,1.60205999132796,0.1196797500423,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.8944744205840971,20,cell cycle
CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,48.53879775666121,1.6179599252220405,12.566159906415255,1.099202581882539,7.341623108665738,50.120675784392596,percent_activity,1.47712125471966,30,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.1253414528794607,1.0891290557018778,0.979881595103461,19.999399185180664,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,67.9781398628599,2.2659379954286636,9.34089425808156,0.9703884557546225,7.346711411798393,55.75620767494357,percent_activity,1.47712125471966,30,,0.8684208352347652,0.6528159041105219,0.02029056723574707,19.999399185180664,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,42.455476783456355,1.4151825594485452,9.992536372908814,0.999675737770255,7.809103377083028,40.158122096340364,percent_activity,1.47712125471966,30,"[""Less than 50% efficacy""]",1.1610214964586276,1.0378505043131159,0.5963788511595762,19.999399185180664,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,65.65834342120141,1.9284303435066814,4.618187485342506,0.6644715600659727,11.349185905224777,53.33240379252649,percent_activity,1.47712125471966,34.04755771567433,,0.7382755334598001,0.7382755334598001,-1.519262290696264,19.999399185180664,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,47.99998523532882,1.5999995078442941,21.346449919072608,1.3293256588104558,6.844875346260387,32.20338983050847,percent_activity,1.47712125471966,30,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.4096139884635301,1.2836175891033685,0.9839803986929424,19.999399185180664,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,57.64601764661512,1.7505534738271513,3.535771278760086,0.5484841636981861,10.976722221189164,47.41319039850851,percent_activity,1.47712125471966,32.93016666356749,"[""Less than 50% efficacy""]",0.906023362325723,0.906023362325723,-2.1893074456846566,19.999399185180664,neurodevelopment
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,98.3964311869445,4.919821559347225,11.251941549927915,1.05122746748448,1.53481347591287,98.4694483204137,percent_activity,1.47712125471966,20,"[""Noisy data"",""Noisy data""]",0.969566112681766,0.871049009465312,0.91987880248498,20,malformation
CCTE_Shafer_MEA_acute_burst_number_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,84.67752181367663,1.0332479052170045,11.28710016763982,1.0525823792185047,27.317588027077427,89.14066756643518,percent_activity,1.60205999132796,81.95276408123229,"[""Borderline active"",""Only one conc above baseline, active""]",1.2373632846949034,1.2373632846949034,0.9333011350418776,20,neuroactivity
CCTE_Shafer_MEA_acute_burst_percentage_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,99.38836845355824,6.790854525187595,16.293754117752695,1.2120211582671903,4.878540105417866,100,percent_activity,1.47712125471966,14.635620316253597,"[""Noisy data"",""Only one conc above baseline, active""]",1.11662300275513,1.11662300275513,1.0926716309781546,19.999399185180664,neuroactivity
CCTE_Shafer_MEA_acute_burst_percentage_std_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,102.90811768188131,1.9124299205762187,22.147261020472957,1.3453200241371222,17.9367126214094,100,percent_activity,1.47712125471966,53.810137864228196,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Noisy data"",""Borderline active""]",1.350359946595695,1.350359946595695,1.224484595782523,19.999399185180664,neuroactivity
CCTE_Shafer_MEA_acute_burst_percentage_std_up,"Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_std_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,91.4239188079089,6.15922183835082,26.154512620119622,1.417546631518309,4.947806785085066,71.63660198464967,percent_activity,1.60205999132796,14.843420355255198,"[""Only one conc above baseline, active"",""Noisy data""]",1.193650111503155,1.193650111503155,1.1177202019680763,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_area_dn,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_area was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_area_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.9998499288977,1.2911025204772535,24.638122841504146,1.3916076162102515,30.9812345200235,100,percent_activity,1.47712125471966,92.9437035600705,"[""Only one conc above baseline, active"",""Borderline active""]",1.4586018751327352,1.4586018751327352,1.2723272942683252,19.999399185180664,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_HWHM was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.99895970611917,3.9291148847605526,25.174345004512638,1.4009581797370199,10.180321626765236,100,percent_activity,1.47712125471966,30.54096488029571,"[""Only one conc above baseline, active""]",1.3426161043044866,1.3426161043044866,1.2816778155343802,19.999399185180664,neuroactivity
CCTE_Shafer_MEA_acute_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,88.82752895195951,1.2516182860679206,10.651237487812995,1.0274000681416267,23.65671438880932,92.76500458810041,percent_activity,1.60205999132796,70.97014316642796,"[""Only one conc above baseline, active""]",1.102307450705538,1.102307450705538,0.90811950360696,20,neuroactivity
CCTE_Shafer_MEA_acute_interburst_interval_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_interburst_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_interburst_interval_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,9.223536552029401,1.0303973629830876,14.578507744279307,1.1637130718836979,2.9838121626290146,9.519403895929747,percent_activity,1.60205999132796,8.951436487887044,"[""Borderline active"",""Only one conc above baseline, active""]",1.3534064476190375,1.3534064476190375,1.0444026531726252,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_up, was analyzed in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, gain-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,59.14897760053536,1.5051440769131208,10.265577568031908,1.011383388928505,13.099294724848574,59.670379617279764,percent_activity,1.60205999132796,39.29788417454572,"[""Only one conc above baseline, active""]",1.0484721843851865,1.0484721843851865,0.8920525499667233,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_spike_number_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_spike_number_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,60.94199952553103,1.1694538090748638,10.109409007081622,1.004725767612225,17.37050209611422,58.36399616965983,percent_activity,1.60205999132796,52.11150628834265,"[""Borderline active"",""Only one conc above baseline, active""]",1.1010957792258398,1.1010957792258398,0.8854436857276611,20,neuroactivity
CCTE_Shafer_MEA_acute_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_acute_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,88.83042446320266,1.2802816072800658,10.651931636746347,1.0274283705082574,23.12783478209955,92.76018096689185,percent_activity,1.60205999132796,69.38350434629865,"[""Only one conc above baseline, active""]",1.096479226831363,1.096479226831363,0.9081477437565815,20,neuroactivity
CCTE_Shafer_MEA_acute_synchrony_index_dn,"Data from the assay component CCTE_Shafer_MEA_acute_synchrony_index was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_synchrony_index_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,105.42189669575276,10.195928042950209,20.82085321442447,1.3184985224235108,3.446535919426672,100,percent_activity,1.47712125471966,10.339607758280016,"[""Only one conc above baseline, active"",""Noisy data""]",1.196163374347069,1.196163374347069,1.19735080961001,19.999399185180664,neuroactivity
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_active_electrodes_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,42.8372765998787,1.618027444754625,6.671757688283984,0.824240264765151,8.825,30.1652892561983,percent_activity,1,26.475,"[""Borderline active"",""Less than 50% efficacy""]",1.52088105243432,1.52088105243432,-2.35656806258892,20,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_peak was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_peak_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,96.1173068361099,3.5460423487291863,94.86832552579268,1.97712123512979,9.03517192629845,44.6307915890027,percent_activity,1,27.1055157788953,"[""Less than 50% efficacy""]",0.749376969629729,0.749376969629729,-0.909464132723553,20,neurodevelopment
CCTE_Simmons_CellTiterGLO_HEK293T,"Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,48.5337490679401,2.426687453397005,96.12052801147269,1.98281614781475,5.60777764752233,25.9938837920489,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.96352504151704,1.94840490828571,1.86353582763965,20,cell cycle
IUF_NPC1_viability_72hr_dn,"Data from the IUF_NPC1_viability component was analyzed at the endpoint IUF_NPC1_viability_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability effects.",, , , ,,,Active,81.45995661651301,2.7153318872171,20.95939478789171,1.321378738040993,4.038717047451669,32.779097387173394,percent_activity,1.30102999566398,30,"[""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.292085176114198,1.2266732292725595,1.202098254159208,20,cell cycle
IUF_NPC2a_ radial_glia_migration_120hr_dn,"Data from the IUF_NPC2a_radial_glia_migration_120hr component was analyzed at the endpoint IUF_NPC2a_ radial_glia_migration_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of migration reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,47.001186720920806,4.2888032561531535,58.50564202123371,1.7671977495101614,5.479522364833141,15.733771664215471,percent_activity,1.30102999566398,10.959044729666282,"[""Less than 50% efficacy""]",0.9502910714634242,1.3416685662509105,0.25951893553575434,20,neurodevelopment
IUF_NPC5_oligodendrocyte_differentiation_120hr_dn,"Data from the IUF_NPC5_oligodendrocyte_differentiation_120hr component was analyzed at the endpoint IUF_NPC5_oligodendrocyte_differentiation_120hr_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of differentiation reporter, loss-of-signal activity can be used to understand developmental effects.",, , , ,,,Active,114.14576320255901,2.421388424610392,5.297234268116159,0.7240491798641167,23.570312396476698,91.29700284430197,percent_activity,1.30102999566398,47.140624792953396,"[""Only one conc above baseline, active""]",0.5375231536189147,0.9825603303956055,-0.44147914034229374,20,neurodevelopment
LTEA_HepaRG_ABCB11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003733.2,ABCB11,"ATP-binding cassette, sub-family B (MDR/TAP), member 11",https://www.ncbi.nlm.nih.gov/gene/8647,"[27,27]",,Active,5.52349805456901,9.841373875543479,74.1195446368365,1.86993274250983,0.187084246719363,4.07119715512701,log2_fold_induction,2,0.561252740158089,,1.42031198026362,1.42031198026362,1.41664347754926,20,transporter
LTEA_HepaRG_ABCB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000918.2,ABCB1,"ATP-binding cassette, sub-family B (MDR/TAP), member 1",https://www.ncbi.nlm.nih.gov/gene/5243,,,Active,1.09480861328789,2.8856685209133026,87.2471439468732,1.94075121914509,0.126465046759354,0.819484819006305,log2_fold_induction,2,0.379395140278062,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.90629325905681,1.90629325905681,1.82138502598847,20,transporter
LTEA_HepaRG_ABCG2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004818.2,ABCG2,"ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)",https://www.ncbi.nlm.nih.gov/gene/9429,,,Active,2.27310740825295,3.7719456400515368,84.93894163365847,1.92910684524042,0.200878417062049,1.78861588609141,log2_fold_induction,2,0.602635251186147,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.87375372647064,1.87375372647064,1.80981569117607,20,transporter
LTEA_HepaRG_ACLY_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001087.2,ACLY,ATP citrate lyase,https://www.ncbi.nlm.nih.gov/gene/47,,,Active,0.990865766225354,2.8302626162802085,46.78321592575331,1.67009007234282,0.116698919330631,0.988594835478969,log2_fold_induction,2,0.350096757991893,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.63727470449231,1.63727470449231,1.55080542680043,20,lyase
LTEA_HepaRG_ACOX1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_009223.2,ACOX1,"acyl-CoA oxidase 1, palmitoyl",https://www.ncbi.nlm.nih.gov/gene/51,,,Active,0.703667715068886,1.73978560575136,8.595536656922588,0.934272996772263,0.134818855982927,0.63144548574201,log2_fold_induction,1.47712125471966,0.404456567948781,,1.07885162821676,1.07885162821676,-0.119732124037103,20,oxidase
LTEA_HepaRG_ADK_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006712.2,ADK,adenosine kinase,https://www.ncbi.nlm.nih.gov/gene/132,,,Active,0.757530379902938,1.5209837564243398,0.17984018369267787,-0.74511326251297,0.166017635341442,0.978416556463803,log2_fold_induction,1.47712125471966,0.498052906024326,,-0.709716285308909,-0.709716285308909,-0.864393576371019,20,kinase
LTEA_HepaRG_ALPP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001623.3,ALPP,"alkaline phosphatase, placental",https://www.ncbi.nlm.nih.gov/gene/250,,,Active,1.75518059829327,1.7491759094819783,0.21424817067382215,-0.669082877547851,0.33447762243899,1.96824999672888,log2_fold_induction,1.47712125471966,1.00343286731697,,-0.653405852670692,-0.653405852670692,-0.78836319385417,20,phosphatase
LTEA_HepaRG_APOA5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_443200.2,APOA5,apolipoprotein A-V,https://www.ncbi.nlm.nih.gov/gene/116519,,,Active,8.74577357037524,10.22512093137536,55.81199678606175,1.74672756055026,0.285107420866427,7.28814464426367,log2_fold_induction,2,0.855322262599281,"[""Noisy data"",""Noisy data""]",1.3828465853195,1.3828465853195,1.38689259075571,20,apolipoprotein
LTEA_HepaRG_BAD_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004313.1,BAD,BCL2-associated agonist of cell death,https://www.ncbi.nlm.nih.gov/gene/572,,,Active,1.62223718465532,1.5306489408673258,83.57872005489936,1.92209571596589,0.353278739350926,1.31047486906238,log2_fold_induction,2,1.05983621805278,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.95650895517309,1.95650895517309,1.8027663298746,20,cell cycle
LTEA_HepaRG_BAX_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_620116.1,BAX,BCL2-associated X protein,https://www.ncbi.nlm.nih.gov/gene/581,,,Active,1.8432004095451,3.6622755750512797,87.61258996305571,1.94256651893754,0.167764583501183,1.3662586960051,log2_fold_induction,2,0.503293750503549,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.88907468227681,1.88907468227681,1.82253401236374,20,cell cycle
LTEA_HepaRG_BCL2L11_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_619527.1,BCL2L11,BCL2-like 11 (apoptosis facilitator),https://www.ncbi.nlm.nih.gov/gene/10018,,,Active,1.21876170664673,2.9661209774683477,88.48960475446552,1.9468922552974,0.136964710914227,0.886316724138343,log2_fold_induction,2,0.410894132742681,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.91019097094454,1.91019097094454,1.82761192621497,20,cell cycle
LTEA_HepaRG_BCL2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000624.2,BCL2,B-cell CLL/lymphoma 2,https://www.ncbi.nlm.nih.gov/gene/596,,,Active,3.11041112424097,6.5493108402292055,81.83562102307575,1.91294238247836,0.15830729879421,2.58960236595722,log2_fold_induction,2,0.47492189638263,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81990860149743,1.81990860149743,1.79365706901786,20,cell cycle
LTEA_HepaRG_BID_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001187.1,BID,BH3 interacting domain death agonist,https://www.ncbi.nlm.nih.gov/gene/637,,,Active,1.19132953010249,1.7069126240200003,0.18376392326649726,-0.735739745747279,0.232648020630518,1.73057643700832,log2_fold_induction,-0.522878745280338,0.697944061891554,,-0.71691046290723,-0.71691046290723,-0.855020059479497,20,cell cycle
LTEA_HepaRG_CASP3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_116786.1,CASP3,"caspase 3, apoptosis-related cysteine peptidase",https://www.ncbi.nlm.nih.gov/gene/836,,,Active,0.540742437869951,1.1753951724565292,0.20769295538701993,-0.682578233789549,0.153350535644343,0.823230434245165,log2_fold_induction,1.47712125471966,0.460051606933029,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",-0.588080438211461,-0.588080438211461,-0.801858547529461,20,protease
LTEA_HepaRG_CASP8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_203520.1,CASP8,"caspase 8, apoptosis-related cysteine peptidase",https://www.ncbi.nlm.nih.gov/gene/841,,,Active,0.739225222493857,1.7177932596280825,0.44859746748347806,-0.348143182516438,0.143444739998166,0.81534934497708,log2_fold_induction,1.47712125471966,0.430334219994498,,-0.193389113925557,-0.193389113925557,-1.37364506205787,20,protease
LTEA_HepaRG_CAT_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001743.1,CAT,catalase,https://www.ncbi.nlm.nih.gov/gene/847,,,Active,2.58976361025865,4.5631329329338675,51.79084239697561,1.71425297503378,0.189180229776443,1.96882976836856,log2_fold_induction,2,0.567540689329329,,1.37044011969586,1.37044011969586,1.11972270705791,20,catalase
LTEA_HepaRG_CDKN1A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000380.1,CDKN1A,"cyclin-dependent kinase inhibitor 1A (p21, Cip1)",https://www.ncbi.nlm.nih.gov/gene/1026,,,Active,2.16539013869708,5.561342626674791,85.53088150608573,1.93212294801715,0.129788211471984,1.68308477865585,log2_fold_induction,2,0.389364634415952,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84967390007883,1.84967390007883,1.81275220255602,20,cell cycle
LTEA_HepaRG_CFLAR_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003870.4,CFLAR,CASP8 and FADD-like apoptosis regulator,https://www.ncbi.nlm.nih.gov/gene/8837,,,Active,0.570096529374059,1.3444440801308781,21.54553648274709,1.33335731246922,0.141346285253843,0.426204412823085,log2_fold_induction,1.47712125471966,0.424038855761529,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.47441619538508,1.47441619538508,1.04256053650041,20,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1,CYP1A1,"cytochrome P450, family 1, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1543,"[57,57]",,Active,1.227262578007,1.3627458217948347,9.983919795419858,0.999301083501561,0.300193564683644,1.4834510338573,log2_fold_induction,1.47712125471966,0.900580694050932,,1.05435078119449,1.05435078119449,0.880020769724167,20,cyp
LTEA_HepaRG_CYP1A2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000752.2,CYP1A2,"cytochrome P450, family 1, subfamily A, polypeptide 2",https://www.ncbi.nlm.nih.gov/gene/1544,"[131,131]",,Active,4.93962684096737,5.202384648232587,86.05599192764289,1.93478111487873,0.316497604782422,3.79793184626316,log2_fold_induction,2,0.949492814347266,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.85684413937656,1.85684413937656,1.8155008006738,20,cyp
LTEA_HepaRG_CYP2B6_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,6.85616374864265,9.094791293421371,82.30448083138566,1.91542347977329,0.251285361310856,5.6652470913496,log2_fold_induction,2,0.753856083932568,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.80189777145339,1.80189777145339,1.79614316469286,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,2.49020750036265,3.3032929672361675,5.007806204342149,0.699647513889808,0.251285361310856,1.84653561704192,log2_fold_induction,2,0.753856083932568,"[""Noisy data"",""Noisy data""]",0.400711733105489,0.400711733105489,-0.0875965152041822,20,cyp
LTEA_HepaRG_CYP2C19_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,4.29142374783683,7.652166192845156,85.66574116146765,1.93280717665865,0.186937207917646,3.32706127063701,log2_fold_induction,2,0.560811623752938,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.82992708319533,1.82992708319533,1.81351560737943,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,0.851465819480714,1.5182742001364469,4.6171206820434065,0.664371226264493,0.186937207917646,0.85166096793446,log2_fold_induction,2,0.560811623752938,"[""Noisy data"",""Noisy data""]",0.723018138301149,0.723018138301149,0.468311472415897,20,cyp
LTEA_HepaRG_CYP2C8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000761.3,CYP2C8,"cytochrome P450, family 2, subfamily C, polypeptide 8",https://www.ncbi.nlm.nih.gov/gene/1558,,,Active,8.37004266801041,12.928724726249353,96.6972980909226,1.98541433922678,0.215799646271804,5.73184410558106,log2_fold_induction,2,0.647398938815412,"[""Noisy data"",""Noisy data""]",1.85084007186055,1.85084007186055,1.86613401200265,20,cyp
LTEA_HepaRG_CYP2C9_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000762.2,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",https://www.ncbi.nlm.nih.gov/gene/1559,,,Active,5.29097325739089,5.61856031738056,53.42528786874785,1.72774687092917,0.313898517206961,5.25600906505607,log2_fold_induction,2,0.941695551620883,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64464482461823,1.64464482461823,1.60841095635723,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1,CYP2E1,"cytochrome P450, family 2, subfamily E, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1571,,,Active,10.0627441674299,21.010997616494524,51.95462318046977,1.71562419929322,0.159642493756543,8.31611931496639,log2_fold_induction,2,0.478927481269629,,1.16380544347208,1.16380544347208,1.31096611597186,20,cyp
LTEA_HepaRG_CYP3A4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_059488.2,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",https://www.ncbi.nlm.nih.gov/gene/1576,,,Active,7.87277541869662,6.63484065405571,89.00905086899958,1.949434170045,0.395526977922934,5.64955725306556,log2_fold_induction,2,1.1865809337688,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.8555739555805,1.8555739555805,1.83015384422203,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",https://www.ncbi.nlm.nih.gov/gene/1576,,,Active,3.5060793442624,2.954774718254106,7.637307530511338,0.88294027863652,0.395526977922934,2.67079338686391,log2_fold_induction,2,1.1865809337688,"[""Noisy data"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Noisy data"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",0.770039426707003,0.770039426707003,0.512840627009486,20,cyp
LTEA_HepaRG_CYP3A5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000768.1,CYP3A5,"cytochrome P450, family 3, subfamily A, polypeptide 5",https://www.ncbi.nlm.nih.gov/gene/1577,,,Active,0.776512286149377,1.0156728953004412,0.13999168170538304,-0.853897769298753,0.254843296413747,1.08220379931049,log2_fold_induction,0.477121254719662,0.764529889241241,"[""Borderline active"",""Borderline active""]",-0.62829133202544,-0.62829133202544,-0.973178131261409,20,cyp
LTEA_HepaRG_CYP3A7_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000756.3,CYP3A7,"cytochrome P450, family 3, subfamily A, polypeptide 7",https://www.ncbi.nlm.nih.gov/gene/1551,,,Active,1.76342105950987,2.2721937965932435,66.04599707446853,1.81984650096416,0.258695812266514,1.35849424138232,log2_fold_induction,2,0.776087436799542,,1.47133558911109,1.47133558911109,-1.36096186367947,20,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2,CYP4A11,"cytochrome P450, family 4, subfamily A, polypeptide 11",https://www.ncbi.nlm.nih.gov/gene/1579,,,Active,9.55286661342289,14.944652376353792,70.1351948756451,1.84593600804566,0.213072127136213,6.95100253396611,log2_fold_induction,2,0.639216381408639,"[""Noisy data"",""Noisy data""]",1.37381633817015,1.37381633817015,1.45226803327355,20,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2,CYP4A22,"cytochrome P450, family 4, subfamily A, polypeptide 22",https://www.ncbi.nlm.nih.gov/gene/284541,,,Active,7.82845353573907,9.691785114463752,66.45374804003905,1.82251948049625,0.269247045935707,6.33630584385141,log2_fold_induction,2,0.807741137807121,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55694456840001,1.55694456840001,1.55266488880753,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2,CYP7A1,"cytochrome P450, family 7, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1581,,,Active,12.119113124836,22.56307347685183,64.29438948810483,1.80817307680188,0.179040518530855,9.85421429405287,log2_fold_induction,2,0.537121555592565,,1.40613532479491,1.40613532479491,1.52052334581215,20,cyp
LTEA_HepaRG_DDIT3_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001181982.1,DDIT3,DNA-damage-inducible transcript 3,https://www.ncbi.nlm.nih.gov/gene/1649,,,Active,5.97116218012406,10.387992635706146,83.94228881993169,1.92398080676628,0.191604621140491,4.79092081521259,log2_fold_induction,2,0.574813863421473,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.80240921418406,1.80240921418406,1.80470049303633,20,dna binding
LTEA_HepaRG_EGF_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001954.2,EGF,epidermal growth factor,https://www.ncbi.nlm.nih.gov/gene/1950,,,Active,1.35636750462193,2.3435937678605416,86.59119720202213,1.93747374420092,0.192918460417901,1.03066933156516,log2_fold_induction,2,0.578755381253703,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.92144024654509,1.92144024654509,1.81819343004819,20,growth factor
LTEA_HepaRG_EGR1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001955.1,EGR1,early growth response 1,https://www.ncbi.nlm.nih.gov/gene/1958,,,Active,0.792149179912293,1.5002934943403552,10.553895433791292,1.02341278694624,0.175998714673843,0.59246220584334,log2_fold_induction,2,0.527996144021529,"[""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only highest conc above baseline, active""]",1.11902674891068,1.11902674891068,0.720066886634883,20,dna binding
LTEA_HepaRG_EGR1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001955.1,EGR1,early growth response 1,https://www.ncbi.nlm.nih.gov/gene/1958,,,Active,0.932653903652725,1.766402869060908,85.6658561524458,1.93280775962114,0.175998714673843,0.72323248481074,log2_fold_induction,2,0.527996144021529,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.94725061949515,1.94725061949515,1.81352744504822,20,dna binding
LTEA_HepaRG_EZR_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003370.2,EZR,ezrin,https://www.ncbi.nlm.nih.gov/gene/7430,,,Active,1.01445092012289,2.1477465420167894,88.69055417395315,1.9478773685513,0.15744423287028,0.733800000530136,log2_fold_induction,2,0.47233269861084,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.94039661456582,1.94039661456582,1.82859697732691,20,membrane protein
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1,FABP1,"fatty acid binding protein 1, liver",https://www.ncbi.nlm.nih.gov/gene/2168,,,Active,9.05794401517552,18.76928148218388,61.542187445485276,1.7891729286781,0.160864691309103,7.37718089485895,log2_fold_induction,2,0.482594073927309,,1.37701295150692,1.37701295150692,1.47444935145455,20,transporter
LTEA_HepaRG_FAS_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000034.1,FAS,Fas cell surface death receptor,https://www.ncbi.nlm.nih.gov/gene/355,,,Active,0.796405720807825,1.4276757805753268,0.22146533192779216,-0.654694248361173,0.185944580145241,0.904664295257807,log2_fold_induction,1.47712125471966,0.557833740435723,,-0.608583580308462,-0.608583580308462,-0.773974562406764,20,cytokine receptor
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4,FASN,fatty acid synthase,https://www.ncbi.nlm.nih.gov/gene/2194,"[58,34,34,58]",,Active,0.656239301469012,1.785511784491887,35.703884514135304,1.55271546908917,0.122511895873739,0.656066845730536,log2_fold_induction,2,0.367535687621217,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56582161462726,1.56582161462726,1.43343302895632,20,lyase
LTEA_HepaRG_FMO3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001002294.1,FMO3,flavin containing monooxygenase 3,https://www.ncbi.nlm.nih.gov/gene/2328,,,Active,2.69644701225375,6.184646711916311,36.301532909026875,1.55992496442662,0.145330155887393,2.69560797982552,log2_fold_induction,2,0.435990467662179,,1.47058492430716,1.47058492430716,1.44064445839254,20,oxidoreductase
LTEA_HepaRG_FOXO1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002006.2,FOXO1,forkhead box O1,https://www.ncbi.nlm.nih.gov/gene/2308,,,Active,0.41695800322115,1.0256842514518623,29.358831959087386,1.46773877318498,0.135505640139235,0.416910415901455,log2_fold_induction,2,0.406516920417705,"[""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.66653068990213,1.66653068990213,1.34845829098777,20,dna binding
LTEA_HepaRG_GADD45A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001915.1,GADD45A,"growth arrest and DNA-damage-inducible, alpha",https://www.ncbi.nlm.nih.gov/gene/1647,,,Active,1.30369395143467,2.152780288468653,0.2033995353317307,-0.691650043562221,0.201862053831487,1.60078240586444,log2_fold_induction,1.47712125471966,0.605586161494461,,-0.699368361295585,-0.699368361295585,-0.81093035734265,20,cell cycle
LTEA_HepaRG_GADD45B_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_056490.2,GADD45B,"growth arrest and DNA-damage-inducible, beta",https://www.ncbi.nlm.nih.gov/gene/4616,,,Active,0.816967572821897,1.9473353448467612,61.72953613966942,1.79049301351759,0.139843671504558,0.61021862468724,log2_fold_induction,2,0.419531014513674,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.80108858172382,1.80108858172382,1.36018018773462,20,mutagenicity response
LTEA_HepaRG_GADD45G_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_006696.1,GADD45G,"growth arrest and DNA-damage-inducible, gamma",https://www.ncbi.nlm.nih.gov/gene/10912,,,Active,3.57998615882286,7.652374846721365,83.14410222135712,1.91983144822105,0.155942271975725,2.91472833176688,log2_fold_induction,2,0.467826815927175,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81695935912072,1.81695935912072,1.80055113453753,20,mutagenicity response
LTEA_HepaRG_GCLC_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001489.1,GCLC,"glutamate-cysteine ligase, catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/2729,,,Active,1.42177756343889,3.2414939945855887,83.363038090368,1.92097353371264,0.146205994911991,1.15312247983032,log2_fold_induction,2,0.438617984735973,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.87715490129042,1.87715490129042,1.80168931372795,20,ligase
LTEA_HepaRG_GSTA2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000837.3,GSTA2,glutathione S-transferase alpha 2,https://www.ncbi.nlm.nih.gov/gene/2939,,,Active,7.35177718217674,11.175523098698365,47.94327396824221,1.68072768797448,0.219282119719688,7.33131662944671,log2_fold_induction,2,0.657846359159064,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55478308601105,1.55478308601105,1.56144736586294,20,transferase
LTEA_HepaRG_HIF1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001521.1,HIF1A,"hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)",https://www.ncbi.nlm.nih.gov/gene/3091,"[122,123,220,150,122,123,220,150]",[801],Active,0.529371034049477,1.3396399105352756,6.94878103629269,0.841908626799889,0.131719733013418,0.435648451926054,log2_fold_induction,1.47712125471966,0.395159199040254,"[""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active""]",1.42406679975803,1.42406679975803,-0.342616421324319,20,dna binding
LTEA_HepaRG_HMGCS2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005509.1,HMGCS2,3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial),https://www.ncbi.nlm.nih.gov/gene/3158,"[60,60]",,Active,11.3157754678829,21.615118042640713,61.864347162378515,1.79144043429469,0.174504027621778,9.18455376459234,log2_fold_induction,2,0.523512082865334,,1.35761991673866,1.35761991673866,1.47643933539937,20,lyase
LTEA_HepaRG_ICAM1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000192.2,ICAM1,intercellular adhesion molecule 1,https://www.ncbi.nlm.nih.gov/gene/3383,,,Active,2.20550045607045,3.854280166895456,84.68634713827389,1.92781340040815,0.190740368332464,1.74440374603035,log2_fold_induction,2,0.572221104997392,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.87087632543108,1.87087632543108,1.80853308672665,20,cell adhesion molecules
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,,IGF1,insulin-like growth factor 1 (somatomedin C),https://www.ncbi.nlm.nih.gov/gene/3479,,,Active,4.59469197414081,9.438935949403671,54.478012695980496,1.73622125656054,0.162260237763032,3.64204998985861,log2_fold_induction,2,0.486780713289096,,1.27060936938274,1.27060936938274,1.25655747593366,20,growth factor
LTEA_HepaRG_IGFBP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000587.1,IGFBP1,insulin-like growth factor binding protein 1,https://www.ncbi.nlm.nih.gov/gene/3484,,,Active,6.75669735276185,7.803003971570242,54.58898576019547,1.73710502537681,0.288636589078576,5.62404850665135,log2_fold_induction,2,0.865909767235728,,1.42107972963993,1.42107972963993,1.37495237872066,20,transporter
LTEA_HepaRG_IL6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000591.1,IL6,interleukin 6,https://www.ncbi.nlm.nih.gov/gene/3569,,,Active,4.34743047220452,5.428991863005056,84.07446291534265,1.92466410163463,0.266926812067961,3.47942140218934,log2_fold_induction,2,0.800780436203883,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84387599093419,1.84387599093419,1.8053837873625,20,cytokine
LTEA_HepaRG_KCNK1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002236.1,KCNK1,"potassium channel, subfamily K, member 1",https://www.ncbi.nlm.nih.gov/gene/3775,,,Active,0.879088720529757,1.2381506388918362,30.388820042987657,1.48271383733667,0.236667142353684,0.878980019908609,log2_fold_induction,2,0.710001427061052,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.56060747381554,1.56060747381554,1.36343336233716,20,ion channel
LTEA_HepaRG_KRT19_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002267.2,KRT19,keratin 19,https://www.ncbi.nlm.nih.gov/gene/3880,,,Active,1.56201400170599,2.8836085193506302,58.701960814830464,1.76865260817842,0.180562420456175,1.20973720040174,log2_fold_induction,2,0.541687261368525,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64466792023074,1.64466792023074,1.33841448385392,20,filaments
LTEA_HepaRG_LDH_cytotoxicity,LDH leakage activity as a measure of membrane integrity and cytotoxicity in the cells.,, , , ,,,Active,9.92275499451549,1.0405832394860701,52.349509655343226,1.71891261810701,0.9535762847205,9.866979342,percent_activity,2,9.535762847205,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.89294026414544,1.66983602199358,1.59958363080422,20,cell cycle
LTEA_HepaRG_LIPC_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000227.2,LIPC,"lipase, hepatic",https://www.ncbi.nlm.nih.gov/gene/3990,,,Active,3.04064986131454,5.849032533962599,57.6076046876172,1.76047981772649,0.173285060031091,2.53387488470243,log2_fold_induction,2,0.519855180093273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.52517910016774,1.52517910016774,1.43300621202969,20,esterase
LTEA_HepaRG_LPL_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000228.1,LPL,lipoprotein lipase,https://www.ncbi.nlm.nih.gov/gene/4023,,,Active,1.06150957345498,2.691522970121175,5.6297356972734125,0.750488006234985,0.131463312189033,0.823396422801715,log2_fold_induction,2,0.394389936567099,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Noisy data"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Noisy data""]",0.323875214332815,0.323875214332815,-1.03282987806492,20,esterase
LTEA_HepaRG_LPL_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000228.1,LPL,lipoprotein lipase,https://www.ncbi.nlm.nih.gov/gene/4023,,,Active,1.53089879537375,3.88168828215852,90.07029491933031,1.95458158476694,0.131463312189033,1.06869794854311,log2_fold_induction,2,0.394389936567099,"[""Only highest conc above baseline, active"",""Noisy data"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Noisy data"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.89712569636274,1.89712569636274,1.83530124339897,20,esterase
LTEA_HepaRG_MIR122_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,,MIR122,microRNA 122,https://www.ncbi.nlm.nih.gov/gene/406906,,,Active,5.75585524837332,5.358231676088686,61.47515019957917,1.788699598505,0.358069328111801,4.34969596984139,log2_fold_induction,2,1.0742079843354,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.51067860853714,1.51067860853714,1.37372201750437,20,microrna
LTEA_HepaRG_MMP10_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002416.1,MMP10,matrix metallopeptidase 10 (stromelysin 2),https://www.ncbi.nlm.nih.gov/gene/4319,,,Active,3.68305398530683,1.669847293827795,82.61442383523911,1.91705587837584,0.735207744029526,3.02738928548392,log2_fold_induction,2,2.20562323208858,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.93880907750044,1.93880907750044,1.79777460498959,20,protease
LTEA_HepaRG_MMP3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002413.1,MMP3,"matrix metallopeptidase 3 (stromelysin 1, progelatinase)",https://www.ncbi.nlm.nih.gov/gene/4314,,,Active,3.32170114482711,3.536314860982106,25.283718878941652,1.40284095291015,0.313103826573539,2.61541524525542,log2_fold_induction,2,0.939311479720617,,0.941156684635756,0.941156684635756,0.312897104395357,20,protease
LTEA_HepaRG_MYC_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002458.2,MYC,v-myc avian myelocytomatosis viral oncogene homolog,https://www.ncbi.nlm.nih.gov/gene/4609,,,Active,2.91516220280854,6.20410284858735,82.3022304742236,1.9154116051943,0.15662550379718,2.40864957674853,log2_fold_induction,2,0.46987651139154,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.82586837125169,1.82586837125169,1.79613129141235,20,dna binding
LTEA_HepaRG_NFE2L2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_006155.2,NFE2L2,"nuclear factor, erythroid 2-like 2",https://www.ncbi.nlm.nih.gov/gene/4780,"[61,61]",[478],Active,1.44994302192646,4.7181448616926955,84.15202370497663,1.92506456443943,0.102437367823581,1.15874375652984,log2_fold_induction,2,0.307312103470743,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.85377377195464,1.85377377195464,1.80578424371629,20,dna binding
LTEA_HepaRG_NFKB1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_068810.3,NFKB1,nuclear factor of kappa light polypeptide gene enhancer in B-cells 1,https://www.ncbi.nlm.nih.gov/gene/4790,,,Active,0.501569328294589,1.4212800178640883,14.34061504435841,1.15656777787592,0.117633241864225,0.383063513072335,log2_fold_induction,1.47712125471966,0.352899725592675,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.42936029674703,1.42936029674703,0.463200667674439,20,dna binding
LTEA_HepaRG_PDK4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002603.1,PDK4,"pyruvate dehydrogenase kinase, isozyme 4",https://www.ncbi.nlm.nih.gov/gene/5166,,,Active,0.48325274723321,1.001172858586092,32.474935060355534,1.51154829129372,0.160895541360588,0.483186621057785,log2_fold_induction,2,0.482686624081764,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.87789378371284,1.87789378371284,1.39226758726995,20,kinase
LTEA_HepaRG_PEG10_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001165908.1,PEG10,paternally expressed 10,https://www.ncbi.nlm.nih.gov/gene/23089,,,Active,1.27973647873075,1.8832183281535761,12.962275117974034,1.11268123490374,0.226515863756396,1.273565113265,log2_fold_induction,1.47712125471966,0.679547591269188,"[""Only one conc above baseline, active"",""Only one conc above baseline, active""]",1.11968731190269,1.11968731190269,0.988719477193854,20,dna binding
LTEA_HepaRG_PPP2R4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_821068.1,PPP2R4,"protein phosphatase 2A activator, regulatory subunit 4",https://www.ncbi.nlm.nih.gov/gene/5524,,,Active,1.1432838870867,3.602758526839965,86.16982271746963,1.93535519944547,0.105778565560197,0.876104906084465,log2_fold_induction,2,0.317335696680591,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.88324685502682,1.88324685502682,1.81566347476467,20,phosphatase
LTEA_HepaRG_SDHB_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002991.2,SDHB,"succinate dehydrogenase complex, subunit B, iron sulfur (Ip)",https://www.ncbi.nlm.nih.gov/gene/6390,,,Active,1.20255809676907,2.0250994150313284,88.17078319984103,1.94532469854274,0.197942232340639,0.881008272098359,log2_fold_induction,2,0.593826697021917,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.94397895032934,1.94397895032934,1.8260443846743,20,oxidoreductase
LTEA_HepaRG_SLC22A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003048.1,SLC22A1,"solute carrier family 22 (organic cation transporter), member 1",https://www.ncbi.nlm.nih.gov/gene/6580,,,Active,5.85126225533312,10.510943588575207,46.37002761423278,1.6662373545265,0.185560957048395,5.83879304970022,log2_fold_induction,2,0.556682871145185,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54395940243577,1.54395940243577,1.54695703951305,20,transporter
LTEA_HepaRG_SLCO1B1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006437.3,SLCO1B1,"solute carrier organic anion transporter family, member 1B1",https://www.ncbi.nlm.nih.gov/gene/10599,,,Active,2.12985188348083,3.9248647941823775,70.40166731938939,1.84758294463978,0.180885371867909,1.46407390383993,log2_fold_induction,2,0.542656115603727,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.6217603696558,1.6217603696558,1.38526408283531,20,transporter
LTEA_HepaRG_STAT3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_644805.1,STAT3,signal transducer and activator of transcription 3 (acute-phase response factor),https://www.ncbi.nlm.nih.gov/gene/6774,,,Active,0.733583514271279,1.6082672641101041,17.25120600340983,1.2368194612828,0.152044279919936,0.511109388978915,log2_fold_induction,1.47712125471966,0.456132839759808,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active""]",1.3877162057009,1.3877162057009,0.569897818299126,20,dna binding
LTEA_HepaRG_SULT2A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003158.2,SULT2A1,"sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1",https://www.ncbi.nlm.nih.gov/gene/6822,,,Active,6.26906250710075,11.1703852275388,70.15560128450636,1.84606235119958,0.187073897614124,4.79818475247506,log2_fold_induction,2,0.561221692842372,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54331619917481,1.54331619917481,1.55927338960461,20,transferase
LTEA_HepaRG_TGFA_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003227.1,TGFA,"transforming growth factor, alpha",https://www.ncbi.nlm.nih.gov/gene/7039,,,Active,2.14766943508856,4.769260796290046,74.77343595582684,1.87374733761298,0.150104983198459,1.63225807194917,log2_fold_induction,2,0.450314949595377,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.72841736773992,1.72841736773992,1.63309042465067,20,growth factor
LTEA_HepaRG_TGFB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,P01137.2,TGFB1,"transforming growth factor, beta 1",https://www.ncbi.nlm.nih.gov/gene/7040,,,Active,1.14178170247431,3.334704438840617,35.813426034188325,1.55404586908706,0.114131224462307,1.14150208439882,log2_fold_induction,2,0.342393673386921,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.50801632905813,1.50801632905813,1.43476412649316,20,growth factor
LTEA_HepaRG_THRSP_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003242.1,THRSP,thyroid hormone responsive,https://www.ncbi.nlm.nih.gov/gene/7069,,,Active,6.09371788163057,6.27040242187556,81.78316225266809,1.91266389910573,0.323940818661091,5.07812045890292,log2_fold_induction,2,0.971822455983273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.82243342689079,1.82243342689079,1.79338358531657,20,growth factor
LTEA_HepaRG_TNFRSF1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001056.1,TNFRSF1A,"tumor necrosis factor receptor superfamily, member 1A",https://www.ncbi.nlm.nih.gov/gene/7132,,,Active,0.993889980601175,1.8957730268842907,0.18019615703034916,-0.744254475278766,0.174755445668978,1.24437664234868,log2_fold_induction,-0.522878745280338,0.524266337006934,,-0.738279222895258,-0.738279222895258,-0.863534789190554,20,cytokine receptor
LTEA_HepaRG_TP53_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,0.431382859479213,1.1725834527592462,0.1797393976222163,-0.745356718135452,0.122630322093241,0.515849645181015,log2_fold_induction,2,0.367890966279723,"[""Less than 50% efficacy"",""Noisy data"",""Borderline active"",""Less than 50% efficacy"",""Noisy data"",""Borderline active""]",-0.649981612251052,-0.649981612251052,-0.864637031885449,20,dna binding
LTEA_HepaRG_TP53_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000537.3,TP53,tumor protein p53,https://www.ncbi.nlm.nih.gov/gene/7157,"[46,46]",,Active,2.20389821500882,5.990628792263149,89.64254566816943,1.95251418112876,0.122630322093241,1.55565979311217,log2_fold_induction,2,0.367890966279723,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.86524471915741,1.86524471915741,1.8332337943347,20,dna binding
LTEA_HepaRG_UGT1A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000454.1,UGT1A1,"UDP glucuronosyltransferase 1 family, polypeptide A1",https://www.ncbi.nlm.nih.gov/gene/54658,,,Active,1.8865086859204,2.848263598620876,87.326170603751,1.9411444160485,0.220778803248623,1.41019524622151,log2_fold_induction,2,0.662336409745869,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.90779834790326,1.90779834790326,1.821862029904,20,transferase
LTEA_HepaRG_UGT1A6_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001063.2,UGT1A6,"UDP glucuronosyltransferase 1 family, polypeptide A6",https://www.ncbi.nlm.nih.gov/gene/54578,,,Active,3.37756653020815,5.988365045511434,238.6683083535331,2.37779475490563,0.188007160804812,2.05012857173967,log2_fold_induction,2,0.564021482414436,"[""Noisy data"",""Noisy data""]",0.459127270812682,0.459127270812682,-0.245390993168537,20,transferase
LTEA_HepaRG_XBP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_005071.2,XBP1,X-box binding protein 1,https://www.ncbi.nlm.nih.gov/gene/7494,,,Active,0.940065400338761,1.8153023129977617,86.48665749480008,1.93694911297543,0.172618704445313,0.71617923489858,log2_fold_induction,2,0.517856113335939,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.94803427867549,1.94803427867549,1.81766879927969,20,dna binding
NVS_ADME_hCYP2B6,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000758.1,CYP2B6,"cytochrome P450, family 2, subfamily B, polypeptide 6",https://www.ncbi.nlm.nih.gov/gene/1555,,,Active,44.7197802057336,2.23598901028668,6.792614359196276,0.832036958852875,1.55763530034319,37.2664835164835,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.735719127249758,-0.144577127660768,-0.166832351815915,20,cyp
NVS_ADME_hCYP2C19,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000760.1,CYP2C19,"cytochrome P450, family 2, subfamily C, polypeptide 19",https://www.ncbi.nlm.nih.gov/gene/1557,,,Active,77.2870011484942,3.86435005742471,6.257818232633503,0.796422944283054,2.60299124232151,64.4058343029184,percent_activity,1.30102999566398,20,,0.387633915123983,-0.0526411030204009,-0.0571035286337939,20,cyp
NVS_ADME_hCYP2C9,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000762.2,CYP2C9,"cytochrome P450, family 2, subfamily C, polypeptide 9",https://www.ncbi.nlm.nih.gov/gene/1559,,,Active,22.4427510547832,1.1221375527391602,7.037525185913987,0.847419962116439,2.17335298616219,22.4375538329027,percent_activity,1.30102999566398,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",0.961563953978921,0.798949279374294,0.728139498384796,20,cyp
NVS_ADME_hCYP3A4,"Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A4, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_059488.2,CYP3A4,"cytochrome P450, family 3, subfamily A, polypeptide 4",https://www.ncbi.nlm.nih.gov/gene/1576,,,Active,73.7929615025887,3.6896480751294347,7.3220584877917085,0.864633193655557,1.85687847312388,61.4941345955958,percent_activity,1.30102999566398,20,,0.527555887752958,0.011127658262406,0.116071653917625,20,cyp
NVS_ENZ_hBACE,"Data from the assay component NVS_ENZ_hBACE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBACE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""aspartate protease"".",P56817.3,BACE1,beta-site APP-cleaving enzyme 1,https://www.ncbi.nlm.nih.gov/gene/23621,,,Active,36.5781433471651,1.828907167358255,12.370095592877732,1.09237305575676,2.62973154362416,30.48178613396,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.19180467446467,0.408280443727756,-0.0719059706401202,20,protease
NVS_ENZ_hPTPN6_Activator,"Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""non-receptor tyrosine phosphatase"". Assay was not developed or optimized to detect gain of signal. Use data with caution.",NP_002822.2,PTPN6,"protein tyrosine phosphatase, non-receptor type 6",https://www.ncbi.nlm.nih.gov/gene/5777,,,Active,32.0846560830036,1.60423280415018,27.819881697931823,1.44435527885356,1.90793690150479,26.7372134038801,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.52486645552155,1.20028752135775,1.0932186379222,20,phosphatase
NVS_GPCR_hDRD1,"Data from the assay component NVS_GPCR_hDRD1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000785.1,DRD1,dopamine receptor D1,https://www.ncbi.nlm.nih.gov/gene/1812,,,Active,27.2993721282879,1.3649686064143949,20.24690641800855,1.30635867553965,3.24915747148213,27.2803738317757,percent_activity,1.69897000433602,20,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.36107694244439,1.27442954133869,1.18707791375355,20,gpcr
NVS_GPCR_hH1,"Data from the assay component NVS_GPCR_hH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000852.1,HRH1,histamine receptor H1,https://www.ncbi.nlm.nih.gov/gene/3269,,,Active,60.9874917586191,3.049374587930955,19.93424782901502,1.29959985324792,2.16547675294364,50.8229098090849,percent_activity,1.69897000433602,20,,1.07851326127525,0.64429577779601,0.622591597656405,20,gpcr
NVS_GPCR_hNK2,"Data from the assay component NVS_GPCR_hNK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TACR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_001048.2,TACR2,tachykinin receptor 2,https://www.ncbi.nlm.nih.gov/gene/6865,,,Active,27.0377061498882,1.3518853074944102,14.552536651979349,1.1629387017712,2.87246328134604,26.9454872516815,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.26167468779109,1.0911239078418,0.955226376858491,20,gpcr
NVS_GPCR_hTXA2,"Data from the assay component NVS_GPCR_hTXA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hTXA2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TBXA2R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_001051.1,TBXA2R,thromboxane A2 receptor,https://www.ncbi.nlm.nih.gov/gene/6915,,,Active,40.8440585004404,1.2393313796593854,24.50393003820469,1.38923574383504,5.49275455712066,40.7054337464252,percent_activity,1.69897000433602,32.956527342724,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.46686880594011,1.36799990878504,1.26994311005963,20,gpcr
NVS_GPCR_mCCKAPeripheral,"Data from the assay component NVS_GPCR_mCCKAPeripheral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCCKAPeripheral, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckar. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_033957.1,Cckar,cholecystokinin A receptor,https://www.ncbi.nlm.nih.gov/gene/12425,,,Active,27.700803188347,1.38504015941735,8.711994266800724,0.940117580946797,3.17593805429475,23.0840026773762,percent_activity,1.69897000433602,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.70759618371562,0.420866619005209,-0.826761452686193,20,gpcr
NVS_GPCR_rabPAF,"Data from the assay component NVS_GPCR_rabPAF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rabPAF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PTAFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",XP_008264091.1,PTAFR,platelet-activating factor receptor,https://www.ncbi.nlm.nih.gov/gene/100354046,,,Active,76.8069453911217,3.2255999546700496,7.959448182072293,0.900882959724078,3.96861289220113,64.0057878316798,percent_activity,1.69897000433602,23.8116773532068,,0.355134589904673,-0.255953184463916,-0.597982013503501,20,gpcr
NVS_IC_rCaDHPRCh_L,"Data from the assay component NVS_IC_rCaDHPRCh_L was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaDHPRCh_L, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""calcium channel"".",P54282.1,Cacna1a,"calcium channel, voltage-dependent, P/Q type, alpha 1A subunit",https://www.ncbi.nlm.nih.gov/gene/25398,,,Active,80.2180882477835,3.6801383421171487,7.016415376822689,0.846115291663873,3.63292901835292,66.8484068745574,percent_activity,1.69897000433602,21.7975741101175,,0.236056795918885,-0.298715045674262,-0.513534233837548,20,ion channel
NVS_IC_rNaCh_site2,"Data from the assay component NVS_IC_rNaCh_site2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rNaCh_site2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Scn1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""sodium channel"".",NP_110502.1,Scn1a,"sodium channel, voltage-gated, type I, alpha subunit",https://www.ncbi.nlm.nih.gov/gene/81574,"[197,96,93,91,94,197,94,93,91,96]",,Active,28.3823908903429,1.108667142599289,18.575761213185665,1.26894661968227,4.26674364194948,28.3719913609155,percent_activity,1.69897000433602,25.6004618516969,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.38943616360248,1.25827022626894,1.14966449943838,20,ion channel
NVS_MP_hPBR,"Data from the assay component NVS_MP_hPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_hPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TSPO. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",NP_000705.2,TSPO,translocator protein (18kDa),https://www.ncbi.nlm.nih.gov/gene/706,,,Active,94.320423846528,4.21933353514116,2.3838975648199403,0.377287589998889,3.72572362676754,83.1144421950994,percent_activity,1.69897000433602,22.3543417606052,,-0.388959488472912,-0.937846990843244,-1.06271739866191,20,transporter
NVS_MP_rPBR,"Data from the assay component NVS_MP_rPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_rPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspo. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""cholesterol transporter"".",NP_036647.1,Tspo,translocator protein,https://www.ncbi.nlm.nih.gov/gene/24230,,,Active,77.9261667444947,2.480853767476093,2.5727273274995075,0.410393759612004,5.23517130581576,75.3387630713157,percent_activity,1.69897000433602,31.4110278348946,,0.261440233449957,-0.111895593846539,-0.423199424822125,20,transporter
NVS_NR_bPR,"Data from the assay component NVS_NR_bPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001192285.1,PGR,progesterone receptor-like,https://www.ncbi.nlm.nih.gov/gene/100848466,,,Active,83.6650888601068,3.3555005305496044,9.015743222278784,0.955001534056745,4.15561891578676,69.7209074041711,percent_activity,1.69897000433602,24.9337134947206,,0.501906935694627,0.0335349831495496,-0.207002337992453,20,nuclear receptor
NVS_NR_cAR,"Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001009012.1,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/747460,,,Active,66.8255012924267,3.3412750646213345,18.325674090778907,1.26305995867585,2.67547881471795,55.6879177453088,percent_activity,1.69897000433602,20,,0.999627387094561,0.646393196245372,0.58265151873525,20,nuclear receptor
NVS_NR_hAR,"Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,"[307,111,19,23,187,117,307,19,23,111,187,117]",,Active,95.6697612364578,4.369127713042454,5.972931705748146,0.776187549070479,3.64946077416744,79.724801061008,percent_activity,1.69897000433602,21.8967646450046,,-0.134041482218346,-0.757162059831186,-0.870353613524116,20,nuclear receptor
NVS_NR_hGR,"Data from the assay component NVS_NR_hGR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hGR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000167.1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",https://www.ncbi.nlm.nih.gov/gene/2908,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,45.0355167703617,1.556093193197316,17.834865165323325,1.25126983034511,4.82356679827413,45.0234741784038,percent_activity,1.69897000433602,28.9414007896448,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.28317031766272,1.2106223189619,1.13182501215837,20,nuclear receptor
NVS_NR_hPR,"Data from the assay component NVS_NR_hPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,66.3817480709452,2.780095855568875,8.296635217403333,0.918901995653405,3.97958388964505,55.3181233933162,percent_activity,1.69897000433602,23.8775033378703,,0.617827292284789,0.126694453837859,-0.228256575970795,20,nuclear receptor
OT_AR_ARSRC1_0960,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1,"AR | SRC","androgen receptor , SRC proto-oncogene, non-receptor tyrosine kinase","https://www.ncbi.nlm.nih.gov/gene/367 , https://www.ncbi.nlm.nih.gov/gene/6714",,,Active,25.2429069149986,1.2621453457499299,38.11408258853053,1.58108547070099,1.6382320441989,24.5762711864407,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.81497962502136,1.33305422149692,1.19723693323709,20,nuclear receptor
OT_FXR_FXRSRC1_0480,"Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1","SRC | NR1H4","SRC proto-oncogene, non-receptor tyrosine kinase , nuclear receptor subfamily 1, group H, member 4","https://www.ncbi.nlm.nih.gov/gene/6714 , https://www.ncbi.nlm.nih.gov/gene/9971",,,Active,40.4365596290246,1.6133548995400688,47.74415208638866,1.67892018488011,5.01272964064537,29.1647744615591,percent_activity,2,25.0636482032268,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.93324540468894,1.406238728413,0.535719666276666,20,nuclear receptor
OT_FXR_FXRSRC1_1440,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1","SRC | NR1H4","SRC proto-oncogene, non-receptor tyrosine kinase , nuclear receptor subfamily 1, group H, member 4","https://www.ncbi.nlm.nih.gov/gene/6714 , https://www.ncbi.nlm.nih.gov/gene/9971",,,Active,53.9003266976324,1.2949923758373731,23.664945650239527,1.37410551138892,8.32442378863878,55.0455432078882,percent_activity,2,41.6221189431939,,1.44037916260247,1.36612691262312,1.25482519740167,20,nuclear receptor
Tanguay_ZF_120hpf_ActivityScore,"Data from the assay component Tanguay_ZF_120hpf_ActivityScore was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_ActivityScore, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,124.628433077364,6.2314216538682,39.37829080787078,1.59525686190826,2.2401450326604,87.4162475200681,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active"",""Noisy data""]",1.24751231079969,0.993206941737542,1.13349298146409,20,malformation
Tanguay_ZF_120hpf_AXIS_up,"Data from the assay component Tanguay_ZF_120hpf_AXIS_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_AXIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,97.4050573420008,4.8702528671000405,28.120937736842695,1.44902979882097,2.63537411808397,79.9798877476993,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.15668978038344,0.924845395009873,0.974392058372765,20,malformation
Tanguay_ZF_120hpf_BRAI_up,"Data from the assay component Tanguay_ZF_120hpf_BRAI_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_BRAI_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,41.3364598402393,2.066822992011965,25.656689103740938,1.40920061163558,2.10016804911582,33.8114850451825,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.39328698171236,0.987098017152807,0.86864587059996,20,malformation
Tanguay_ZF_120hpf_CFIN_up,"Data from the assay component Tanguay_ZF_120hpf_CFIN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_CFIN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,64.0567229351609,3.2028361467580453,7.5946801815248905,0.880509490071957,2.13485958486518,64.0564746542832,percent_activity,1.77815125038364,20,,0.83710752673109,0.759746445396009,0.759756870540544,20,malformation
Tanguay_ZF_120hpf_EYE_up,"Data from the assay component Tanguay_ZF_120hpf_EYE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_EYE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,70.1889765737951,3.509448828689755,44.476778306642714,1.64813332141751,2.30241738279413,46.7139627408717,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.34163527668163,0.910248382637188,0.916178080140667,20,malformation
Tanguay_ZF_120hpf_JAW_up,"Data from the assay component Tanguay_ZF_120hpf_JAW_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_JAW_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,72.8047537243877,3.640237686219385,42.70473972821695,1.6304760793242,2.62920060840169,50.7357404429992,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.37097595744728,1.06708440832054,1.04318770420699,20,malformation
Tanguay_ZF_120hpf_OTIC_up,"Data from the assay component Tanguay_ZF_120hpf_OTIC_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_OTIC_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,43.5061607966284,2.17530803983142,30.347830686513227,1.48212765242781,1.97768058396892,34.9336022547784,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.44808823948548,1.09317078640617,1.01910463826378,20,malformation
Tanguay_ZF_120hpf_PE_up,"Data from the assay component Tanguay_ZF_120hpf_PE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,82.4550698495473,4.122753492477365,23.11607532151772,1.36391410090363,2.88514919770174,66.8448521614193,percent_activity,1.77815125038364,20,,1.03939612106746,0.75314196254379,0.737735652387018,20,malformation
Tanguay_ZF_120hpf_PFIN_up,"Data from the assay component Tanguay_ZF_120hpf_PFIN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PFIN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,43.7799872552157,2.188999362760785,31.998760023751906,1.50513314940503,2.18262089117193,36.3283699915524,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.47529775096451,1.20558782330732,1.12644744439524,20,malformation
Tanguay_ZF_120hpf_PIG_up,"Data from the assay component Tanguay_ZF_120hpf_PIG_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_PIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,79.3717026212726,3.96858513106363,35.588990468369055,1.55131566880646,1.93284296757538,56.6129348051621,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.26506760090575,0.882927300415269,0.973280838375619,20,malformation
Tanguay_ZF_120hpf_SNOU_up,"Data from the assay component Tanguay_ZF_120hpf_SNOU_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SNOU_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,54.9734756332107,2.7486737816605347,26.778601263935272,1.42778788861254,2.70483677373105,44.8898314146845,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.29646917937602,1.01575838316216,0.911490599991224,20,malformation
Tanguay_ZF_120hpf_SOMI_up,"Data from the assay component Tanguay_ZF_120hpf_SOMI_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SOMI_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,42.4650482000758,2.12325241000379,9.012863708368707,0.954862803758042,1.97596700497027,42.4649250317752,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",0.946923822481136,0.830639290387886,0.804781389920264,20,malformation
Tanguay_ZF_120hpf_SWIM_up,"Data from the assay component Tanguay_ZF_120hpf_SWIM_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_SWIM_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,38.4431850920036,1.9221592546001802,16.188722446933163,1.20921257721913,1.87649540155528,35.0182566607584,percent_activity,1.77815125038364,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.22904470545015,0.777798766576974,0.671489621949242,20,malformation
Tanguay_ZF_120hpf_TRUN_up,"Data from the assay component Tanguay_ZF_120hpf_TRUN_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TRUN_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,86.3416067954731,4.317080339773655,29.475469832538042,1.46946073638129,2.21501896749265,70.0681355604232,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.21590849181728,0.944132423412576,1.00484710802734,20,malformation
Tanguay_ZF_120hpf_TR_up,"Data from the assay component Tanguay_ZF_120hpf_TR_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_TR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,57.6999127086962,2.88499563543481,34.54452808893268,1.53837926418528,2.25069751143067,41.6958411706556,percent_activity,1.77815125038364,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.36327391995862,0.980144807428439,0.931453430419419,20,malformation
Tanguay_ZF_120hpf_YSE_up,"Data from the assay component Tanguay_ZF_120hpf_YSE_up was analyzed into 1 assay endpoints. This assay endpoint, Tanguay_ZF_120hpf_YSE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defects as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the MALFORMATION intended target family, where the subfamily is TOTAL.",, , , ,,,Active,80.5307360655425,4.026536803277125,22.287197611690825,1.34805546380136,3.19325001944697,64.177136981408,percent_activity,1.77815125038364,20,,0.997828926074742,0.714806587944706,0.653172715105386,20,malformation
TOX21_AhR_LUC_Agonist_viability,"TOX21_AhR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,44.6689335955902,1.5934147706235648,71.30499700110043,1.85311996595229,4.67224378936707,33.7733662027,percent_activity,1.95424250943932,28.0334627362024,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.89467527232736,1.79081405818463,1.6781572430722,20,cell cycle
TOX21_AP1_BLA_Agonist_ch2,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,22.9125377337379,1.075300055140394,4.1931656793053875,0.622542022476683,3.55134017774949,26.8907816387,percent_activity,1.47712125471966,21.3080410664969,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.16464244399138,0.593137632622755,0.161989049421835,20,channel 2
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1,"JUN | FOS|JUN","jun proto-oncogene , FBJ murine osteosarcoma viral oncogene homolog|jun proto-oncogene","https://www.ncbi.nlm.nih.gov/gene/3725 , https://www.ncbi.nlm.nih.gov/gene/4029",,,Active,23.8245762833401,1.191228814167005,6.361757898511121,0.803577137682173,2.7369041511147,25.2500360627,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.26206944836982,0.625444569833123,0.194606600892562,20,dna binding
TOX21_AR_BLA_Antagonist_ch2,"Data from the assay component TOX21_AR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,118.709292006839,2.2482460015259846,40.406939055693286,1.60645595260618,8.80014108229746,92.3906375221,percent_activity,1.90308998699194,52.8008464937848,,1.56030654395125,1.34593391324034,1.14915954990269,20,channel 2
TOX21_AR_BLA_Antagonist_ratio,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,86.6277308966718,3.3200316193021107,28.214786381862368,1.45047676651357,4.34874025461246,82.262633965,percent_activity,1.90308998699194,26.0924415276748,,1.33555659328175,1.21425481186693,1.15043971163103,20,nuclear receptor
TOX21_AR_BLA_Antagonist_viability,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,23.3132699689402,1.011018689402547,43.64057218385189,1.63989043611109,3.8431979898606,23.2313995085,percent_activity,1.90308998699194,23.0591879391636,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.88462423985156,1.63870708845302,1.52061009981853,20,cell cycle
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,97.354250360901,3.0303281409269642,17.11953713808302,1.23349201845481,5.35443940025589,87.6090966701,percent_activity,1.95424250943932,32.1266364015353,,1.00719004865334,0.715348680106953,0.531376715778188,20,nuclear receptor
TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,"[307,111,19,23,187,117,307,19,23,111,187,117]",,Active,100.312085127597,3.3567701721122964,75.46904118873253,1.87776883244684,4.98058550254545,82.2643552544,percent_activity,1.95424250943932,29.8835130152727,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83122917831357,1.78315567013394,1.75848851874285,20,nuclear receptor
TOX21_Aromatase_Inhibition,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",NP_000094.2,CYP19A1,"cytochrome P450, family 19, subfamily A, polypeptide 1",https://www.ncbi.nlm.nih.gov/gene/1588,"[122,123,7,153,25,122,123,7,153,25]",[964],Active,58.7008387854108,2.187381942435618,55.387927604942604,1.74341511588553,4.47268624701549,42.8405046278,percent_activity,1.95424250943932,26.8361174820929,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.70967962201318,1.50450310844147,1.31183377174326,20,cyp
TOX21_CAR_Agonist_viabillity,"TOX21_CAR_Agonist_viabillity used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,28.6544772753313,1.432723863766565,71.78251986223812,1.85601869979071,2.77710640921686,24.6949213046,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.90149242272721,1.80760893860472,1.7367381796317,20,cell cycle
TOX21_CAR_Antagonist,"Data from the assay component TOX21_CAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_001070948.1,NR1I3,"nuclear receptor subfamily 1, group I, member 3",https://www.ncbi.nlm.nih.gov/gene/9970,,,Active,56.1951658567904,2.0697625757729536,34.67292031326339,1.53999042148115,4.52508953720649,54.274598737,percent_activity,1.95424250943932,27.1505372232389,,1.53590097177119,1.47061245818706,1.40674791198817,20,nuclear receptor
TOX21_CAR_Antagonist_viability,"TOX21_CAR_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,34.6890554723032,1.73445277361516,81.39272766659997,1.91058560298062,2.40485484020376,23.8003656305,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.92734011864264,1.83799566107703,1.79130528880994,20,cell cycle
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,56.8374960424341,2.841874802121705,72.96890892263991,1.86313785245495,2.57636017956492,48.4703856873,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.82997998867038,1.76275828035584,1.74385627800871,20,cell cycle
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,124.616327691075,5.192213260606391,36.454574833173886,1.56175203745867,4.0001030208237,102.0174677757,percent_activity,1.95424250943932,24.0006181249422,,1.16200443606914,0.937249180993688,0.948915313214584,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,"RAD54L | XRCC6P1","RAD54 like (S. cerevisiae) , X-ray repair cross complementing 6 pseudogene 1","https://www.ncbi.nlm.nih.gov/gene/8438 , https://www.ncbi.nlm.nih.gov/gene/387703",,,Active,127.348406717885,5.904125451375089,52.998095843535665,1.72426026621398,3.59489896137582,104.4775646852,percent_activity,1.95424250943932,21.5693937682549,,1.48251942696433,1.36237956984461,1.39021418736345,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",,REV3L,"REV3 like, DNA directed polymerase zeta catalytic subunit",https://www.ncbi.nlm.nih.gov/gene/5980,,,Active,128.411871773304,4.900839513703664,50.4304334808726,1.70269270120577,4.36700254498032,92.4823193273,percent_activity,1.95424250943932,26.2020152698819,,1.29905063230513,1.0577444303555,1.05113699772621,20,cell cycle
TOX21_ERa_BLA_Agonist_ch1,"Data from the assay component TOX21_ERa_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,36.0169796983604,1.80084898491802,21.24819640884833,1.32732207213092,2.92546209770346,25.7189871227,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.48081268180742,0.544505570649467,-0.191270156169198,20,channel 1
TOX21_ERa_BLA_Antagonist_ch2,"Data from the assay component TOX21_ERa_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,86.2038010882121,2.213963962829594,75.168168192852,1.87603396685605,6.48940110253932,44.8156709287,percent_activity,1.90308998699194,38.9364066152359,"[""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",1.81335209638758,1.47776224787765,1.16570630343074,20,channel 2
TOX21_ERa_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,72.1652048558124,3.60826024279062,70.18059601996906,1.8462170522106,3.3294568553358,44.7950886837,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.74019198218774,1.64398834471533,1.60321619969976,20,nuclear receptor
TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_000116.2,ESR1,estrogen receptor 1,https://www.ncbi.nlm.nih.gov/gene/2099,,,Active,32.2944004908323,1.37076968579492,39.44010174282824,1.59593802661126,3.92655318948354,27.3962795882,percent_activity,1.95424250943932,23.5593191369012,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.81844933260104,1.47152190336381,1.1031744482039,20,nuclear receptor
TOX21_ERb_BLA_Antagonist_ch2,"Data from the assay component TOX21_ERb_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,68.8168680360717,1.881150219628287,54.75261321483629,1.73840485187197,6.09705587907717,66.0609443587,percent_activity,1.95424250943932,36.582335274463,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.74527361038016,1.68324596585469,1.61912449071009,20,channel 2
TOX21_ERb_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERb_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERb_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_001428.1,ESR2,estrogen receptor 2 (ER beta),https://www.ncbi.nlm.nih.gov/gene/2100,,,Active,52.8105706761942,2.1775275698435093,38.32257726536055,1.58345470850897,4.04208970819059,51.3469126805,percent_activity,1.95424250943932,24.2525382491435,,1.56707672265071,1.46213908076148,1.36324431577006,20,nuclear receptor
TOX21_ERR_Antagonist,"Data from the assay component TOX21_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_004442.3,ESRRA,estrogen-related receptor alpha,https://www.ncbi.nlm.nih.gov/gene/2101,,,Active,71.6381980807199,3.390202284359942,35.12057816256379,1.54556165674273,3.52182515338437,69.739349233,percent_activity,1.95424250943932,21.1309509203062,,1.44544861072405,1.3439893153341,1.29312144688951,20,nuclear receptor
TOX21_ERR_viability,"TOX21_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,26.4304756263266,1.32152378131633,45.90193795539591,1.66183102160627,2.25399102610353,26.531830945,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.72342942836637,1.60386874748981,1.54255062203074,20,cell cycle
TOX21_FXR_BLA_antagonist_ratio,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1,NR1H4,"nuclear receptor subfamily 1, group H, member 4",https://www.ncbi.nlm.nih.gov/gene/9971,"[27,61,27,61]",[479],Active,41.8473898150981,2.092369490754905,78.35357000572058,1.89405878891518,2.78938673282934,21.8171267516,percent_activity,1.90308998699194,20,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.87737971355216,1.63230887195325,1.479253878944,20,nuclear receptor
TOX21_GR_BLA_Antagonist_ch2,"Data from the assay component TOX21_GR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,89.0508031725838,1.786317493310708,40.64340618299346,1.60899009751626,8.30860168158384,71.2045458005,percent_activity,1.90308998699194,49.851610089503,,1.6851381578481,1.30967128099584,0.912991239863619,20,channel 2
TOX21_GR_BLA_Antagonist_ratio,"Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000167.1,NR3C1,"nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)",https://www.ncbi.nlm.nih.gov/gene/2908,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,91.1601512222282,2.3949537783886052,40.27429463980064,1.60502794296525,6.34390470252021,75.9601797778,percent_activity,1.90308998699194,38.0634282151213,,1.51653500974223,1.25081786983725,1.02088416018091,20,nuclear receptor
TOX21_HRE_BLA_Agonist_viability,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,34.7661109332928,1.73830554666464,31.941603385173234,1.50435671279982,3.0508964104962,34.5986083749,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.5232605882646,1.44023823339992,1.36745361698138,20,cell cycle
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,53.7506606384405,1.3902165932355524,46.90501609534919,1.6712192893258,6.44391923052108,53.4861191171,percent_activity,1.95424250943932,38.6635153831265,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.72230607359443,1.63990357868432,1.55193897355442,20,cell morphology
TOX21_MMP_viability,"TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,30.6719936159055,1.533599680795275,51.435751827617686,1.71126509222544,3.32276785161468,28.7403739387,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.77158197726823,1.64107715202425,1.50026722160336,20,cell cycle
TOX21_NFkB_BLA_agonist_viability,"TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,31.3982794436972,1.2794880111950664,21.681634858437967,1.33609202617028,4.08995358155937,32.0529626151,percent_activity,1.47712125471966,24.5397214893562,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.40529662834352,1.31198709668593,1.21681171234234,20,cell cycle
TOX21_p53_BLA_p2_ch1,"Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,26.52743862066,1.326371931033,73.66197151622008,1.86724333829241,2.8966141715805,22.1061989014,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.92803234573296,1.82820078988822,1.74795692661533,20,channel 1
TOX21_p53_BLA_p4_ch1,"Data from the assay component TOX21_p53_BLA_p4_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p4_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,33.329035720607,1.66645178603035,63.631424541987755,1.80367164606821,2.74402988187153,31.3699751503,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.82570057440143,1.74315774185877,1.68439122217599,20,channel 1
TOX21_p53_BLA_p4_viability,"TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,49.3408505563881,2.061692383782506,54.571450430431234,1.73696549685739,3.98870130064896,41.1173754649,percent_activity,1.95424250943932,23.9322078038938,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.72811949360735,1.56867022224017,1.41228650418964,20,cell cycle
TOX21_PGC_ERR_Antagonist,"Data from the assay component TOX21_PGC_ERR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PGC_ERR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESRRA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is orphan.",NP_004442.3,ESRRA,estrogen-related receptor alpha,https://www.ncbi.nlm.nih.gov/gene/2101,,,Active,80.1398806222536,2.4036359177329722,42.86948718260251,1.63214828838355,5.55685104879492,72.653773869,percent_activity,1.95424250943932,33.3411062927695,,1.57085719557714,1.39048187999626,1.23496805294764,20,nuclear receptor
TOX21_PGC_ERR_viability,"TOX21_PGC_ERR_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,34.1930621591616,1.70965310795808,63.039475652197275,1.7996125921353,2.5904653717656,26.682516883,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.84138650787565,1.65056503589362,1.5319965805635,20,cell cycle
TOX21_PR_BLA_Antagonist_ch1,"Data from the assay component TOX21_PR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,38.3875112870432,1.347524315332776,29.85206852252706,1.47497442983035,4.74790582629342,31.6447173646,percent_activity,1.60205999132796,28.4874349577605,"[""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.56618723605017,1.42943265641046,1.28535279580764,20,channel 1
TOX21_PR_BLA_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,75.6939184822213,1.8219744220445457,9.391844678553705,0.972750901641526,6.92416585421295,77.2198511267,percent_activity,1.95424250943932,41.5449951252777,,1.00297767353582,0.822843781042589,0.633978339528355,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,74.5817499401506,3.72908749700753,6.1239331389571525,0.78703044042915,2.51198214229767,79.1983231815,percent_activity,1.60205999132796,20,,0.557481154885063,0.287289122354876,0.284652195312256,20,nuclear receptor
TOX21_PR_BLA_Followup_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,91.447412333719,1.1177623914788815,12.980524884749732,1.11329225409313,27.2709754866379,89.847638674,percent_activity,1.95424250943932,81.81292645991371,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.5994670801354318,1.5994670801354318,0.6139036746769314,20,channel 2
TOX21_PR_BLA_Followup_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Followup_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Followup_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,85.8090441341013,1.779229683126959,17.795564278310312,1.25031176357173,8.03803325186715,82.7518261462,percent_activity,1.95424250943932,48.2281995112029,,1.2999397500052223,1.0634170037965087,0.8131737424649488,20,nuclear receptor
TOX21_PR_LUC_Followup_Antagonist,"Data from the assay component TOX21_PR_LUC_Followup_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_LUC_Followup_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is steroidal.",NP_000917.3,PGR,progesterone receptor,https://www.ncbi.nlm.nih.gov/gene/5241,,,Active,108.056321983502,2.180148814204086,45.470170638532224,1.65772658401012,8.26062279781809,89.3649057911,percent_activity,1.95424250943932,49.5637367869085,,1.62521644324337,1.41984248710416,1.22647902547741,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1,NR1I2,"nuclear receptor subfamily 1, group I, member 2",https://www.ncbi.nlm.nih.gov/gene/8856,,,Active,149.088150638431,7.454407531921549,54.526042624491055,1.73660397873004,1.80636679455099,98.4605198221,percent_activity,1.95424250943932,20,,0.896731516416908,0.260410490938772,0.746993941019813,20,nuclear receptor
TOX21_PXR_viability,"The assay component endpoint  TOX21_PXR_viability was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,27.3828056103813,1.3691402805190651,49.85664221841104,1.69772302597039,2.43196946437473,29.2800916926,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.75182410716943,1.6427438292363,1.57844268817383,20,cell cycle
TOX21_RAR_LUC_Antagonist,"Data from the assay component TOX21_RAR_LUC_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RAR_LUC_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene RARA. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where subfamily is non-steroidal.",NP_000955.1,RARA,"retinoic acid receptor, alpha",https://www.ncbi.nlm.nih.gov/gene/5914,,,Active,55.5748912824579,1.8678125923353448,46.76375264388213,1.66990935465271,4.95899959044,44.224965889,percent_activity,1.95424250943932,29.75399754264,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.70035955210524,1.45377189004038,1.19800809566419,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_005051.2,RORC,RAR-related orphan receptor C,https://www.ncbi.nlm.nih.gov/gene/6097,,,Active,69.2807776203055,1.3296314025788,30.480622731741047,1.48402383557426,8.68420845631059,54.1634918892,percent_activity,1.95424250943932,52.1052507378635,"[""Borderline active"",""Borderline active""]",1.89049210428323,1.2985594332653,0.679268027778074,20,nuclear receptor
TOX21_RT_HEK293_FLO_24hr_viability,"TOX21_RT_HEK293_FLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,38.5423875265586,1.4348122020984897,2.11404669158398,0.32511457505908,4.47705368342379,32.1186565067,percent_activity,0.477121254719662,26.8623221005427,"[""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",0.400120333083966,0.268760581431959,0.12723228658265,20,cell cycle
TOX21_RT_HEK293_FLO_40hr_viability,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,39.1138405540819,1.3705884055686606,1.399838311374823,0.146077875297552,4.75633195144065,37.3937472133,percent_activity,0.477121254719662,28.5379917086439,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active"",""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Cell viability assay fit with gnls winning model"",""Only one conc above baseline, active""]",0.199966399470516,0.11597251450294,0.0267975558059949,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,41.5849843406883,1.7128107754996804,42.62200116605615,1.62963383662578,4.04646609105207,34.6541537721,percent_activity,1.90308998699194,24.2787965463124,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.68895646520789,1.47436365165949,1.24461164575627,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,39.6065192442844,1.6429978112140993,36.08830490520436,1.55736648340046,4.0177086637968,39.1919221375,percent_activity,1.90308998699194,24.1062519827808,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.59093284791402,1.49452262390002,1.39035898824311,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,46.8968716960577,1.9114146045308829,33.17266514074859,1.52078036477916,4.08919407864135,46.7847942652,percent_activity,1.90308998699194,24.5351644718481,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.52665652865385,1.45503973592723,1.38158656431922,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,68.5092763987478,2.7270196909499016,34.261209638594075,1.53480269225741,4.18706647811088,57.0910636794,percent_activity,1.90308998699194,25.1223988686653,,1.38835139943477,1.13441518668006,0.945878774951976,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,74.7179111670561,3.0000718569907394,31.549135116993796,1.49898745806302,4.15089564121323,62.2649260049,percent_activity,1.90308998699194,24.9053738472794,,1.30447279103753,1.04735373148742,0.88242251028006,20,cell cycle
TOX21_RT_HEPG2_GLO_24hr_ctrl_viability,"TOX21_RT_HEPG2_GLO_24hr_ctrl_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,20.1637488038439,1.008187440192195,32.159141209938845,1.50730444266458,1.22724010465665,20.1489336414,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.76816092606129,1.42593445901909,1.38802412854223,20,cell cycle
TOX21_SBE_BLA_Antagonist_ratio,"Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.",NP_005891.1,SMAD1,SMAD family member 1,https://www.ncbi.nlm.nih.gov/gene/4086,,,Active,47.7644415801245,2.341115527763543,58.7605419500564,1.76908579264636,3.40040470833105,32.2107069643,percent_activity,1.90308998699194,20.4024282499863,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.71820626077244,1.543116346794,1.38818940099558,20,growth factor receptor
TOX21_SHH_3T3_GLI3_Agonist_viability,"TOX21_SHH_3T3_GLI3_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,25.7703055475278,1.2885152773763902,77.48295443530267,1.88920617206884,2.74374658540332,20.0534468988,percent_activity,1.95424250943932,20,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.95668507453783,1.84813851877483,1.76992585076881,20,cell cycle
TOX21_SHH_3T3_GLI3_Antagonist_viability,"TOX21_SHH_3T3_GLI3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,25.2444699501972,1.26222349750986,37.34195796767669,1.57219708576797,2.48726544475101,22.4743434486,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.83690290830922,1.40046150140648,1.13768614354097,20,cell cycle
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2","THRA | THRB","thyroid hormone receptor, alpha , thyroid hormone receptor, beta","https://www.ncbi.nlm.nih.gov/gene/7067 , https://www.ncbi.nlm.nih.gov/gene/7068",,,Active,97.315628926486,4.337333201495384,51.39697366048688,1.71093754776483,3.73945711206963,95.559075504,percent_activity,1.95424250943932,22.4367426724178,,1.64551259318139,1.60030509510549,1.59165721867752,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist_viability,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,88.8797866786251,2.2178171096781267,36.61657496838946,1.56367771894181,6.67922423139783,73.7392546696,percent_activity,1.95424250943932,40.075345388387,,1.51047447034226,1.23046179011865,0.97045999654402,20,cell cycle
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,57.530457703467,1.514852723354715,31.902832239626413,1.50382924015563,12.6591971211703,57.5235779497567,percent_activity,2,37.9775913635109,,1.53986900954386,1.53986900954386,1.38454844267,19.999399185180664,nuclear receptor
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist, was analyzed in the positive fitting direction relative to DMSO as the baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",,AR,androgen receptor,https://www.ncbi.nlm.nih.gov/gene/367,,,Active,20.2588088838784,1.01294044419392,0.032519013086072045,-1.48786264320641,2.03792638311569,26.6080187214736,percent_activity,0,20,"[""Borderline active"",""Borderline active""]",-1.25175900767753,-1.53341817857846,-1.6071921251081,19.999399185180664,nuclear receptor